US20220273655A1 - Producing astrocytes using small molecules - Google Patents
Producing astrocytes using small molecules Download PDFInfo
- Publication number
- US20220273655A1 US20220273655A1 US17/656,999 US202217656999A US2022273655A1 US 20220273655 A1 US20220273655 A1 US 20220273655A1 US 202217656999 A US202217656999 A US 202217656999A US 2022273655 A1 US2022273655 A1 US 2022273655A1
- Authority
- US
- United States
- Prior art keywords
- cells
- astrocytes
- inhibitor
- combination
- gfap
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 210000001130 astrocyte Anatomy 0.000 title claims abstract description 206
- 150000003384 small molecules Chemical class 0.000 title claims description 53
- 210000004027 cell Anatomy 0.000 claims abstract description 173
- 238000000034 method Methods 0.000 claims abstract description 31
- 210000000130 stem cell Anatomy 0.000 claims abstract description 30
- 210000004556 brain Anatomy 0.000 claims abstract description 19
- 230000004064 dysfunction Effects 0.000 claims abstract description 13
- 230000004770 neurodegeneration Effects 0.000 claims abstract description 11
- 208000015122 neurodegenerative disease Diseases 0.000 claims abstract description 11
- 239000003112 inhibitor Substances 0.000 claims description 76
- 150000001875 compounds Chemical class 0.000 claims description 73
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 47
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 47
- 210000002950 fibroblast Anatomy 0.000 claims description 46
- 230000008672 reprogramming Effects 0.000 claims description 41
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 36
- 210000001519 tissue Anatomy 0.000 claims description 32
- 230000000392 somatic effect Effects 0.000 claims description 26
- 101710096379 Lysine-specific histone demethylase 1 Proteins 0.000 claims description 22
- FHYUGAJXYORMHI-UHFFFAOYSA-N SB 431542 Chemical compound C1=CC(C(=O)N)=CC=C1C1=NC(C=2C=C3OCOC3=CC=2)=C(C=2N=CC=CC=2)N1 FHYUGAJXYORMHI-UHFFFAOYSA-N 0.000 claims description 19
- IGLYMJRIWWIQQE-QUOODJBBSA-N (1S,2R)-2-phenylcyclopropan-1-amine (1R,2S)-2-phenylcyclopropan-1-amine Chemical compound N[C@H]1C[C@@H]1C1=CC=CC=C1.N[C@@H]1C[C@H]1C1=CC=CC=C1 IGLYMJRIWWIQQE-QUOODJBBSA-N 0.000 claims description 17
- AQGNHMOJWBZFQQ-UHFFFAOYSA-N CT 99021 Chemical compound CC1=CNC(C=2C(=NC(NCCNC=3N=CC(=CC=3)C#N)=NC=2)C=2C(=CC(Cl)=CC=2)Cl)=N1 AQGNHMOJWBZFQQ-UHFFFAOYSA-N 0.000 claims description 17
- 239000003276 histone deacetylase inhibitor Substances 0.000 claims description 17
- 101150038319 oac1 gene Proteins 0.000 claims description 17
- 229960003741 tranylcypromine Drugs 0.000 claims description 17
- HIJMSZGHKQPPJS-UHFFFAOYSA-N 3-(6-methylpyridin-2-yl)-n-phenyl-4-quinolin-4-ylpyrazole-1-carbothioamide Chemical compound CC1=CC=CC(C=2C(=CN(N=2)C(=S)NC=2C=CC=CC=2)C=2C3=CC=CC=C3N=CC=2)=N1 HIJMSZGHKQPPJS-UHFFFAOYSA-N 0.000 claims description 16
- 102000019058 Glycogen Synthase Kinase 3 beta Human genes 0.000 claims description 16
- 108010051975 Glycogen Synthase Kinase 3 beta Proteins 0.000 claims description 16
- 229940121372 histone deacetylase inhibitor Drugs 0.000 claims description 16
- HWJRIFZDXJKJJN-UHFFFAOYSA-N n-(1h-pyrrolo[2,3-c]pyridin-5-yl)benzamide Chemical compound C=1C=2C=CNC=2C=NC=1NC(=O)C1=CC=CC=C1 HWJRIFZDXJKJJN-UHFFFAOYSA-N 0.000 claims description 16
- BERLXWPRSBJFHO-UHFFFAOYSA-N 2-(5-chloro-2-fluorophenyl)-n-pyridin-4-ylpteridin-4-amine Chemical compound FC1=CC=C(Cl)C=C1C1=NC(NC=2C=CN=CC=2)=C(N=CC=N2)C2=N1 BERLXWPRSBJFHO-UHFFFAOYSA-N 0.000 claims description 8
- CJLMANFTWLNAKC-UHFFFAOYSA-N 3-[6-amino-5-(3,4,5-trimethoxyphenyl)pyridin-3-yl]phenol Chemical compound COC1=C(OC)C(OC)=CC(C=2C(=NC=C(C=2)C=2C=C(O)C=CC=2)N)=C1 CJLMANFTWLNAKC-UHFFFAOYSA-N 0.000 claims description 8
- BBDGBGOVJPEFBT-UHFFFAOYSA-N 5-[6-(4-piperazin-1-ylphenyl)pyrazolo[1,5-a]pyrimidin-3-yl]quinoline Chemical compound C1CNCCN1C1=CC=C(C2=CN3N=CC(=C3N=C2)C=2C3=CC=CN=C3C=CC=2)C=C1 BBDGBGOVJPEFBT-UHFFFAOYSA-N 0.000 claims description 8
- IVRXNBXKWIJUQB-UHFFFAOYSA-N LY-2157299 Chemical compound CC1=CC=CC(C=2C(=C3CCCN3N=2)C=2C3=CC(=CC=C3N=CC=2)C(N)=O)=N1 IVRXNBXKWIJUQB-UHFFFAOYSA-N 0.000 claims description 8
- SAGZIBJAQGBRQA-UHFFFAOYSA-N n-(oxan-4-yl)-4-[4-(5-pyridin-2-yl-1h-pyrazol-4-yl)pyridin-2-yl]benzamide Chemical compound C=1C=C(C=2N=CC=C(C=2)C2=C(NN=C2)C=2N=CC=CC=2)C=CC=1C(=O)NC1CCOCC1 SAGZIBJAQGBRQA-UHFFFAOYSA-N 0.000 claims description 8
- IHLVSLOZUHKNMQ-UHFFFAOYSA-N 4-[2-[4-(2-pyridin-2-yl-5,6-dihydro-4h-pyrrolo[1,2-b]pyrazol-3-yl)quinolin-7-yl]oxyethyl]morpholine Chemical compound C=1C=C2C(C=3C(=NN4CCCC4=3)C=3N=CC=CC=3)=CC=NC2=CC=1OCCN1CCOCC1 IHLVSLOZUHKNMQ-UHFFFAOYSA-N 0.000 claims description 7
- FVRYPYDPKSZGNS-UHFFFAOYSA-N 5-[6-(4-methoxyphenyl)pyrazolo[1,5-a]pyrimidin-3-yl]quinoline Chemical compound C1=CC(OC)=CC=C1C1=CN2N=CC(C=3C4=CC=CN=C4C=CC=3)=C2N=C1 FVRYPYDPKSZGNS-UHFFFAOYSA-N 0.000 claims description 7
- BTUOOXPZOVNPMF-UHFFFAOYSA-N 2-[4-(1,3-benzodioxol-5-yl)-2-tert-butyl-1h-imidazol-5-yl]-6-methylpyridine;hydrochloride Chemical compound Cl.CC1=CC=CC(C2=C(N=C(N2)C(C)(C)C)C=2C=C3OCOC3=CC=2)=N1 BTUOOXPZOVNPMF-UHFFFAOYSA-N 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 5
- 210000000601 blood cell Anatomy 0.000 claims description 4
- 230000002485 urinary effect Effects 0.000 claims description 4
- 210000001789 adipocyte Anatomy 0.000 claims description 3
- 210000001968 dental pulp cell Anatomy 0.000 claims description 3
- 210000002510 keratinocyte Anatomy 0.000 claims description 3
- 208000012902 Nervous system disease Diseases 0.000 abstract description 16
- 208000025966 Neurological disease Diseases 0.000 abstract description 11
- -1 small molecule compounds Chemical class 0.000 abstract description 9
- 108700019146 Transgenes Proteins 0.000 abstract description 7
- 208000024827 Alzheimer disease Diseases 0.000 abstract description 3
- 102100039289 Glial fibrillary acidic protein Human genes 0.000 description 85
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 description 85
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 description 77
- 230000014509 gene expression Effects 0.000 description 41
- 108090000623 proteins and genes Proteins 0.000 description 39
- 239000005090 green fluorescent protein Substances 0.000 description 37
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 36
- 229930195712 glutamate Natural products 0.000 description 34
- 238000011282 treatment Methods 0.000 description 33
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 31
- 230000003140 astrocytic effect Effects 0.000 description 31
- 208000011403 Alexander disease Diseases 0.000 description 26
- 108010023918 S100 Calcium Binding Protein beta Subunit Proteins 0.000 description 26
- 102000011425 S100 Calcium Binding Protein beta Subunit Human genes 0.000 description 26
- 241000699666 Mus <mouse, genus> Species 0.000 description 23
- 238000006243 chemical reaction Methods 0.000 description 23
- 238000012744 immunostaining Methods 0.000 description 19
- 210000002569 neuron Anatomy 0.000 description 18
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical group [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 17
- 239000011575 calcium Substances 0.000 description 17
- 229910052791 calcium Inorganic materials 0.000 description 17
- 210000001082 somatic cell Anatomy 0.000 description 15
- VAAUVRVFOQPIGI-SPQHTLEESA-N ceftriaxone Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C(=O)NN1C VAAUVRVFOQPIGI-SPQHTLEESA-N 0.000 description 13
- 229960004755 ceftriaxone Drugs 0.000 description 13
- 239000000126 substance Substances 0.000 description 13
- 239000003550 marker Substances 0.000 description 12
- 238000003753 real-time PCR Methods 0.000 description 12
- 101150057182 GFAP gene Proteins 0.000 description 11
- 239000002609 medium Substances 0.000 description 11
- 230000001537 neural effect Effects 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 10
- 230000001965 increasing effect Effects 0.000 description 9
- 210000002241 neurite Anatomy 0.000 description 9
- 230000000638 stimulation Effects 0.000 description 9
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 8
- 230000006698 induction Effects 0.000 description 8
- 230000001105 regulatory effect Effects 0.000 description 8
- 108050009621 Synapsin Proteins 0.000 description 7
- 102000001435 Synapsin Human genes 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 230000035772 mutation Effects 0.000 description 7
- 230000009207 neuronal maturation Effects 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 210000001202 rhombencephalon Anatomy 0.000 description 7
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 6
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 6
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 description 6
- 101000979001 Homo sapiens Methionine aminopeptidase 2 Proteins 0.000 description 6
- 101000969087 Homo sapiens Microtubule-associated protein 2 Proteins 0.000 description 6
- 102100023174 Methionine aminopeptidase 2 Human genes 0.000 description 6
- 101710126211 POU domain, class 5, transcription factor 1 Proteins 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 210000004129 prosencephalon Anatomy 0.000 description 6
- 238000001890 transfection Methods 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 5
- 102000007354 PAX6 Transcription Factor Human genes 0.000 description 5
- 102100035423 POU domain, class 5, transcription factor 1 Human genes 0.000 description 5
- 239000012091 fetal bovine serum Substances 0.000 description 5
- 238000003384 imaging method Methods 0.000 description 5
- 230000001939 inductive effect Effects 0.000 description 5
- 210000005155 neural progenitor cell Anatomy 0.000 description 5
- 230000004845 protein aggregation Effects 0.000 description 5
- 238000011002 quantification Methods 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- LBPKYPYHDKKRFS-UHFFFAOYSA-N 1,5-naphthyridine, 2-[3-(6-methyl-2-pyridinyl)-1h-pyrazol-4-yl]- Chemical compound CC1=CC=CC(C2=C(C=NN2)C=2N=C3C=CC=NC3=CC=2)=N1 LBPKYPYHDKKRFS-UHFFFAOYSA-N 0.000 description 4
- 108010036280 Aquaporin 4 Proteins 0.000 description 4
- 102000012002 Aquaporin 4 Human genes 0.000 description 4
- 102100039077 Cytosolic 10-formyltetrahydrofolate dehydrogenase Human genes 0.000 description 4
- 238000000116 DAPI staining Methods 0.000 description 4
- 101000959030 Homo sapiens Cytosolic 10-formyltetrahydrofolate dehydrogenase Proteins 0.000 description 4
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 4
- 229930182816 L-glutamine Natural products 0.000 description 4
- 229940123628 Lysine (K)-specific demethylase 1A inhibitor Drugs 0.000 description 4
- 101150009249 MAP2 gene Proteins 0.000 description 4
- 101100310657 Mus musculus Sox1 gene Proteins 0.000 description 4
- 101150081664 PAX6 gene Proteins 0.000 description 4
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 230000001973 epigenetic effect Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 239000000543 intermediate Substances 0.000 description 4
- 201000006417 multiple sclerosis Diseases 0.000 description 4
- 210000004248 oligodendroglia Anatomy 0.000 description 4
- 238000002054 transplantation Methods 0.000 description 4
- 102100027766 Atlastin-1 Human genes 0.000 description 3
- 101100518995 Caenorhabditis elegans pax-3 gene Proteins 0.000 description 3
- 102100031562 Excitatory amino acid transporter 2 Human genes 0.000 description 3
- 101150026630 FOXG1 gene Proteins 0.000 description 3
- 101710204931 Ferroptosis suppressor protein 1 Proteins 0.000 description 3
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 3
- 101000866287 Homo sapiens Excitatory amino acid transporter 2 Proteins 0.000 description 3
- 101100018264 Mus musculus Hoxb4 gene Proteins 0.000 description 3
- 101100518997 Mus musculus Pax3 gene Proteins 0.000 description 3
- 101150111110 NKX2-1 gene Proteins 0.000 description 3
- 229930040373 Paraformaldehyde Natural products 0.000 description 3
- 238000010240 RT-PCR analysis Methods 0.000 description 3
- 108091005735 TGF-beta receptors Proteins 0.000 description 3
- 102000016715 Transforming Growth Factor beta Receptors Human genes 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000001369 bisulfite sequencing Methods 0.000 description 3
- 230000028956 calcium-mediated signaling Effects 0.000 description 3
- 238000003501 co-culture Methods 0.000 description 3
- 238000011109 contamination Methods 0.000 description 3
- 210000003618 cortical neuron Anatomy 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000002493 microarray Methods 0.000 description 3
- 229920002866 paraformaldehyde Polymers 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- KYVDGDMQERQKOY-UHFFFAOYSA-N 2-chloro-1-(4,5-dibromo-2-thiophenyl)ethanone Chemical compound ClCC(=O)C1=CC(Br)=C(Br)S1 KYVDGDMQERQKOY-UHFFFAOYSA-N 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 201000006474 Brain Ischemia Diseases 0.000 description 2
- 101150008656 COL1A1 gene Proteins 0.000 description 2
- 206010008120 Cerebral ischaemia Diseases 0.000 description 2
- 102100035784 Decorin Human genes 0.000 description 2
- 101150059401 EGR2 gene Proteins 0.000 description 2
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 2
- 238000000729 Fisher's exact test Methods 0.000 description 2
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 2
- 108050005433 Glutaredoxin-2 Proteins 0.000 description 2
- 102000008157 Histone Demethylases Human genes 0.000 description 2
- 108010074870 Histone Demethylases Proteins 0.000 description 2
- 102000003964 Histone deacetylase Human genes 0.000 description 2
- 108090000353 Histone deacetylase Proteins 0.000 description 2
- 101000891649 Homo sapiens Transcription elongation factor A protein-like 1 Proteins 0.000 description 2
- 208000023105 Huntington disease Diseases 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 101100233118 Mus musculus Insc gene Proteins 0.000 description 2
- 101150092239 OTX2 gene Proteins 0.000 description 2
- 101150041192 Otx1 gene Proteins 0.000 description 2
- DPWPWRLQFGFJFI-UHFFFAOYSA-N Pargyline Chemical compound C#CCN(C)CC1=CC=CC=C1 DPWPWRLQFGFJFI-UHFFFAOYSA-N 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- JDSJDASOXWCHPN-UHFFFAOYSA-N TDZD-8 Chemical compound O=C1N(C)SC(=O)N1CC1=CC=CC=C1 JDSJDASOXWCHPN-UHFFFAOYSA-N 0.000 description 2
- 101150054439 TRHR gene Proteins 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 101150024658 aldh1l1 gene Proteins 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000007541 cellular toxicity Effects 0.000 description 2
- 206010008118 cerebral infarction Diseases 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000012137 double-staining Methods 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 210000001671 embryonic stem cell Anatomy 0.000 description 2
- 206010015037 epilepsy Diseases 0.000 description 2
- 238000010195 expression analysis Methods 0.000 description 2
- QQUXFYAWXPMDOE-UHFFFAOYSA-N kenpaullone Chemical compound C1C(=O)NC2=CC=CC=C2C2=C1C1=CC(Br)=CC=C1N2 QQUXFYAWXPMDOE-UHFFFAOYSA-N 0.000 description 2
- 210000003140 lateral ventricle Anatomy 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- 108010082117 matrigel Proteins 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 238000010208 microarray analysis Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000003061 neural cell Anatomy 0.000 description 2
- 210000001178 neural stem cell Anatomy 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- MFBOGIVSZKQAPD-UHFFFAOYSA-M sodium butyrate Chemical compound [Na+].CCCC([O-])=O MFBOGIVSZKQAPD-UHFFFAOYSA-M 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000000225 synapse Anatomy 0.000 description 2
- 230000000946 synaptic effect Effects 0.000 description 2
- RTKIYFITIVXBLE-QEQCGCAPSA-N trichostatin A Chemical compound ONC(=O)/C=C/C(/C)=C/[C@@H](C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-QEQCGCAPSA-N 0.000 description 2
- 238000010200 validation analysis Methods 0.000 description 2
- ATBAETXFFCOZOY-DAXSKMNVSA-N (4z)-4-(2-amino-4-oxo-1h-imidazol-5-ylidene)-2-bromo-1,5,6,7-tetrahydropyrrolo[2,3-c]azepin-8-one Chemical compound N1C(N)=NC(=O)\C1=C/1C(C=C(Br)N2)=C2C(=O)NCC\1 ATBAETXFFCOZOY-DAXSKMNVSA-N 0.000 description 1
- ZRHRPGSSSVYBRG-UHFFFAOYSA-N 2-[(3-iodophenyl)methylthio]-5-pyridin-4-yl-1,3,4-oxadiazole Chemical compound IC1=CC=CC(CSC=2OC(=NN=2)C=2C=CN=CC=2)=C1 ZRHRPGSSSVYBRG-UHFFFAOYSA-N 0.000 description 1
- FKJSFKCZZIXQIP-UHFFFAOYSA-N 2-bromo-1-(4-bromophenyl)ethanone Chemical compound BrCC(=O)C1=CC=C(Br)C=C1 FKJSFKCZZIXQIP-UHFFFAOYSA-N 0.000 description 1
- OMKHWTRUYNAGFG-IEBDPFPHSA-N 3-deazaneplanocin a Chemical compound C1=NC=2C(N)=NC=CC=2N1[C@@H]1C=C(CO)[C@@H](O)[C@H]1O OMKHWTRUYNAGFG-IEBDPFPHSA-N 0.000 description 1
- 101150009360 ATF4 gene Proteins 0.000 description 1
- 101150073415 Aqp4 gene Proteins 0.000 description 1
- 102000010637 Aquaporins Human genes 0.000 description 1
- 108010063290 Aquaporins Proteins 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- VPQUNNRSYOVKIL-WQLSENKSSA-N CC1=CC2=C(C1)C(=O)CCC/C2=C1/NC(N)=NC1=O Chemical compound CC1=CC2=C(C1)C(=O)CCC/C2=C1/NC(N)=NC1=O VPQUNNRSYOVKIL-WQLSENKSSA-N 0.000 description 1
- PATYHUUYADUHQS-UHFFFAOYSA-N CCC(=O)c1ccc(C)cc1 Chemical compound CCC(=O)c1ccc(C)cc1 PATYHUUYADUHQS-UHFFFAOYSA-N 0.000 description 1
- TZAZIMVWKRVSPM-UHFFFAOYSA-N CCc1cc(CCCCc2ccc(C3C=CC=C3)c(-c3ccc(C)cc3Cl)c2)ccc1C(C)C Chemical compound CCc1cc(CCCCc2ccc(C3C=CC=C3)c(-c3ccc(C)cc3Cl)c2)ccc1C(C)C TZAZIMVWKRVSPM-UHFFFAOYSA-N 0.000 description 1
- UJXPPWJFCFEVFT-UHFFFAOYSA-N CCc1nc2c(c3cc(OC)c(OC)cc13)C(=O)C(C)C2=O Chemical compound CCc1nc2c(c3cc(OC)c(OC)cc13)C(=O)C(C)C2=O UJXPPWJFCFEVFT-UHFFFAOYSA-N 0.000 description 1
- MDZCSIDIPDZWKL-UHFFFAOYSA-N CHIR-98014 Chemical compound C1=C([N+]([O-])=O)C(N)=NC(NCCNC=2N=C(C(=CN=2)N2C=NC=C2)C=2C(=CC(Cl)=CC=2)Cl)=C1 MDZCSIDIPDZWKL-UHFFFAOYSA-N 0.000 description 1
- OAQVMNQONZQCLR-UHFFFAOYSA-N CN1CCC(C(C)(C)C)CC1 Chemical compound CN1CCC(C(C)(C)C)CC1 OAQVMNQONZQCLR-UHFFFAOYSA-N 0.000 description 1
- CYDLLRMDLNBJSW-UHFFFAOYSA-N COc1ccc(-c2cnc3c(-c4cccc5ccccc45)cnn3c2)cc1 Chemical compound COc1ccc(-c2cnc3c(-c4cccc5ccccc45)cnn3c2)cc1 CYDLLRMDLNBJSW-UHFFFAOYSA-N 0.000 description 1
- SBFNQISHBPMCQN-UHFFFAOYSA-N COc1ccc(CNC(=O)NC2=CC=C(C(C)=O)C2)cc1 Chemical compound COc1ccc(CNC(=O)NC2=CC=C(C(C)=O)C2)cc1 SBFNQISHBPMCQN-UHFFFAOYSA-N 0.000 description 1
- 101100388543 Caenorhabditis elegans glt-1 gene Proteins 0.000 description 1
- WGZOTBUYUFBEPZ-UHFFFAOYSA-N Cc1cccc(-c2[nH]c(C(C)(C)C)nc2-c2ccc3c(c2)OCO3)n1.Cl Chemical compound Cc1cccc(-c2[nH]c(C(C)(C)C)nc2-c2ccc3c(c2)OCO3)n1.Cl WGZOTBUYUFBEPZ-UHFFFAOYSA-N 0.000 description 1
- KJTYZDORHCDZPS-UHFFFAOYSA-N Cc1cccc(-c2[nH]ncc2-c2ccnc3ccccc23)n1 Chemical compound Cc1cccc(-c2[nH]ncc2-c2ccnc3ccccc23)n1 KJTYZDORHCDZPS-UHFFFAOYSA-N 0.000 description 1
- NOEUFOLNMLPTQY-UHFFFAOYSA-N Cc1cccc(CCc2nnc(-c3ccncc3)o2)c1 Chemical compound Cc1cccc(CCc2nnc(-c3ccncc3)o2)c1 NOEUFOLNMLPTQY-UHFFFAOYSA-N 0.000 description 1
- 101150088103 Col12a1 gene Proteins 0.000 description 1
- 101150008975 Col3a1 gene Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 102100023580 Cyclic AMP-dependent transcription factor ATF-4 Human genes 0.000 description 1
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
- 230000007067 DNA methylation Effects 0.000 description 1
- 238000000018 DNA microarray Methods 0.000 description 1
- 101100518002 Danio rerio nkx2.2a gene Proteins 0.000 description 1
- 108090000738 Decorin Proteins 0.000 description 1
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 108010000722 Excitatory Amino Acid Transporter 1 Proteins 0.000 description 1
- 108010000720 Excitatory Amino Acid Transporter 2 Proteins 0.000 description 1
- 102100031563 Excitatory amino acid transporter 1 Human genes 0.000 description 1
- OUVXYXNWSVIOSJ-UHFFFAOYSA-N Fluo-4 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=C(C=2)C2=C3C=C(F)C(=O)C=C3OC3=CC(O)=C(F)C=C32)N(CC(O)=O)CC(O)=O)=C1 OUVXYXNWSVIOSJ-UHFFFAOYSA-N 0.000 description 1
- 102100020871 Forkhead box protein G1 Human genes 0.000 description 1
- LRULVYSBRWUVGR-FCHUYYIVSA-N GSK2879552 Chemical compound C1=CC(C(=O)O)=CC=C1CN1CCC(CN[C@H]2[C@@H](C2)C=2C=CC=CC=2)CC1 LRULVYSBRWUVGR-FCHUYYIVSA-N 0.000 description 1
- 102000034575 Glutamate transporters Human genes 0.000 description 1
- 108091006151 Glutamate transporters Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 102000002254 Glycogen Synthase Kinase 3 Human genes 0.000 description 1
- 108010014905 Glycogen Synthase Kinase 3 Proteins 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 108700014808 Homeobox Protein Nkx-2.2 Proteins 0.000 description 1
- 102100027886 Homeobox protein Nkx-2.2 Human genes 0.000 description 1
- 101000905743 Homo sapiens Cyclic AMP-dependent transcription factor ATF-4 Proteins 0.000 description 1
- 101000999377 Homo sapiens Interferon-related developmental regulator 1 Proteins 0.000 description 1
- 101100460496 Homo sapiens NKX2-2 gene Proteins 0.000 description 1
- 101001111328 Homo sapiens Nuclear factor 1 A-type Proteins 0.000 description 1
- 101001092197 Homo sapiens RNA binding protein fox-1 homolog 3 Proteins 0.000 description 1
- 101000596334 Homo sapiens TSC22 domain family protein 1 Proteins 0.000 description 1
- 101000652332 Homo sapiens Transcription factor SOX-1 Proteins 0.000 description 1
- 101000635938 Homo sapiens Transforming growth factor beta-1 proprotein Proteins 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 101150094516 Ifrd1 gene Proteins 0.000 description 1
- 102100036527 Interferon-related developmental regulator 1 Human genes 0.000 description 1
- 229930195714 L-glutamate Natural products 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 101000596402 Mus musculus Neuronal vesicle trafficking-associated protein 1 Proteins 0.000 description 1
- 101000800539 Mus musculus Translationally-controlled tumor protein Proteins 0.000 description 1
- AELCINSCMGFISI-UHFFFAOYSA-N NC1CC1c1ccccc1 Chemical compound NC1CC1c1ccccc1 AELCINSCMGFISI-UHFFFAOYSA-N 0.000 description 1
- LYUQWQRTDLVQGA-UHFFFAOYSA-N NCCCc1ccccc1 Chemical compound NCCCc1ccccc1 LYUQWQRTDLVQGA-UHFFFAOYSA-N 0.000 description 1
- ZNRHOWOYSDCTNT-UHFFFAOYSA-N Nc1cccc(-c2cc3c(Oc4cccc(Cl)c4)ncnc3[nH]2)c1 Chemical compound Nc1cccc(-c2cc3c(Oc4cccc(Cl)c4)ncnc3[nH]2)c1 ZNRHOWOYSDCTNT-UHFFFAOYSA-N 0.000 description 1
- 208000029726 Neurodevelopmental disease Diseases 0.000 description 1
- 102100024006 Nuclear factor 1 A-type Human genes 0.000 description 1
- AIWGTQPXLOIBSY-UHFFFAOYSA-N O=C(CCCCCCC(=O)NO)Cc1ccccc1 Chemical compound O=C(CCCCCCC(=O)NO)Cc1ccccc1 AIWGTQPXLOIBSY-UHFFFAOYSA-N 0.000 description 1
- KOXQZZJLYHHQBD-UHFFFAOYSA-N O=C1CC(=O)C(c2cn(CCCO)c3ncccc23)=C1c1cnccn1 Chemical compound O=C1CC(=O)C(c2cn(CCCO)c3ncccc23)=C1c1cnccn1 KOXQZZJLYHHQBD-UHFFFAOYSA-N 0.000 description 1
- DDLZLOKCJHBUHD-WAVHTBQISA-N O=C1Nc2cc(Br)ccc2/C1=C1/Nc2ccccc2/C1=N\O Chemical compound O=C1Nc2cc(Br)ccc2/C1=C1/Nc2ccccc2/C1=N\O DDLZLOKCJHBUHD-WAVHTBQISA-N 0.000 description 1
- XDBZVTPUJCIWTP-AEELKVOVSA-N O=C=O.[H]c1ccc(CN2CCC(CCC3C[C@H]3c3ccccc3)CC2)cc1 Chemical compound O=C=O.[H]c1ccc(CN2CCC(CCC3C[C@H]3c3ccccc3)CC2)cc1 XDBZVTPUJCIWTP-AEELKVOVSA-N 0.000 description 1
- 108010019644 Oligodendrocyte Transcription Factor 2 Proteins 0.000 description 1
- 102100026058 Oligodendrocyte transcription factor 2 Human genes 0.000 description 1
- 108010032788 PAX6 Transcription Factor Proteins 0.000 description 1
- 238000010220 Pearson correlation analysis Methods 0.000 description 1
- RMUCZJUITONUFY-UHFFFAOYSA-N Phenelzine Chemical compound NNCCC1=CC=CC=C1 RMUCZJUITONUFY-UHFFFAOYSA-N 0.000 description 1
- 102100035530 RNA binding protein fox-1 homolog 3 Human genes 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 102000012980 SLC1A2 Human genes 0.000 description 1
- 241000316887 Saissetia oleae Species 0.000 description 1
- 101000781972 Schizosaccharomyces pombe (strain 972 / ATCC 24843) Protein wos2 Proteins 0.000 description 1
- 101150041420 Slc1a2 gene Proteins 0.000 description 1
- 102000008063 Small Heat-Shock Proteins Human genes 0.000 description 1
- 108010088928 Small Heat-Shock Proteins Proteins 0.000 description 1
- 101150047615 TGFB1I1 gene Proteins 0.000 description 1
- 102100035051 TSC22 domain family protein 1 Human genes 0.000 description 1
- 101150100033 TSC22D1 gene Proteins 0.000 description 1
- 101001009610 Toxoplasma gondii Dense granule protein 5 Proteins 0.000 description 1
- 102100030248 Transcription factor SOX-1 Human genes 0.000 description 1
- 102100030742 Transforming growth factor beta-1 proprotein Human genes 0.000 description 1
- 108050008367 Transmembrane emp24 domain-containing protein 7 Proteins 0.000 description 1
- RTKIYFITIVXBLE-UHFFFAOYSA-N Trichostatin A Natural products ONC(=O)C=CC(C)=CC(C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-UHFFFAOYSA-N 0.000 description 1
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 1
- 0 [1*]c1c(C(=O)Cc2ccc3c(c2)C([4*])=[Y]([5*])N3)ccc([3*])c1[2*] Chemical compound [1*]c1c(C(=O)Cc2ccc3c(c2)C([4*])=[Y]([5*])N3)ccc([3*])c1[2*] 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 239000003782 beta lactam antibiotic agent Substances 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- OOKYRHQSMYPHOE-UHFFFAOYSA-N c1ccc(C2=NN3CCCC3C2c2ccnc3cc(OCCN4CCOCC4)ccc23)nc1 Chemical compound c1ccc(C2=NN3CCCC3C2c2ccnc3cc(OCCN4CCOCC4)ccc23)nc1 OOKYRHQSMYPHOE-UHFFFAOYSA-N 0.000 description 1
- 238000010805 cDNA synthesis kit Methods 0.000 description 1
- SWUIQEBPZIHZQS-UHFFFAOYSA-N calone Chemical compound O1CC(=O)COC2=CC(C)=CC=C21 SWUIQEBPZIHZQS-UHFFFAOYSA-N 0.000 description 1
- 210000005056 cell body Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 1
- 229940095074 cyclic amp Drugs 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000017858 demethylation Effects 0.000 description 1
- 238000010520 demethylation reaction Methods 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 230000003492 excitotoxic effect Effects 0.000 description 1
- 231100000063 excitotoxicity Toxicity 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 210000003953 foreskin Anatomy 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000011223 gene expression profiling Methods 0.000 description 1
- 230000004077 genetic alteration Effects 0.000 description 1
- 231100000118 genetic alteration Toxicity 0.000 description 1
- 230000002518 glial effect Effects 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 238000003365 immunocytochemistry Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000010832 independent-sample T-test Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002743 insertional mutagenesis Methods 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 108091050724 let-7b stem-loop Proteins 0.000 description 1
- 108091030917 let-7b-1 stem-loop Proteins 0.000 description 1
- 108091082924 let-7b-2 stem-loop Proteins 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- YAEMHJKFIIIULI-UHFFFAOYSA-N n-(4-methoxybenzyl)-n'-(5-nitro-1,3-thiazol-2-yl)urea Chemical compound C1=CC(OC)=CC=C1CNC(=O)NC1=NC=C([N+]([O-])=O)S1 YAEMHJKFIIIULI-UHFFFAOYSA-N 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000003988 neural development Effects 0.000 description 1
- 230000007472 neurodevelopment Effects 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 230000006576 neuronal survival Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 229920002113 octoxynol Polymers 0.000 description 1
- 229960001779 pargyline Drugs 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 229960000964 phenelzine Drugs 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 101150055666 sox6 gene Proteins 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000012085 transcriptional profiling Methods 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 description 1
- 229960000237 vorinostat Drugs 0.000 description 1
- 239000002132 β-lactam antibiotic Substances 0.000 description 1
- 229940124586 β-lactam antibiotics Drugs 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0622—Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/01—Modulators of cAMP or cGMP, e.g. non-hydrolysable analogs, phosphodiesterase inhibitors, cholera toxin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/065—Modulators of histone acetylation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/15—Transforming growth factor beta (TGF-β)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
- C12N2501/603—Oct-3/4
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
- C12N2501/72—Transferases (EC 2.)
- C12N2501/727—Kinases (EC 2.7.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/999—Small molecules not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
- C12N2506/1307—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from adult fibroblasts
Definitions
- Astrocytes are glial cells that are located in all regions of the brain (Molofsky et al., 2012; Verkhratsky et al., 2012). They have long been held as the supporting components in neural tissues (Wang and Bordey, 2008; Sofroniew and Vinters, 2010). However, over the past decades, increasing evidence has established a variety of essential functions for astrocytes in neural development and in the pathogenesis of neurological diseases (Verkhratsky et al., 2012).
- AxD Alexander disease
- this disclosure relates to a method of reprogramming or converting somatic tissue or cells into astrocytes or astroglial progenitor cells by contacting the somatic tissue or cells with one or more small molecules only without introducing any transgenes.
- the somatic tissue or cells are autologous tissue or cells.
- the somatic tissue or cells that can be reprogrammed or converted include but are not limited to fibroblasts, urinary cells, blood cells, adipocytes, keratinocytes, and dental pulp cells.
- At least one small molecule is a TGF- ⁇ inhibitor, including but not limited to TGF- ⁇ inhibitor 616452, A-83-01, SB-431542, SD-208, LY 2109761, GW 788388, LDN-212854, A 77-01, LY2157299, K02288, ML347, and SB-505124 hydrochloride.
- a TGF- ⁇ inhibitor can be used in combination with one or more of a histone deacetylase inhibitor, a GSK3 ⁇ inhibitor, a lysine specific histone demethylase 1 (LSD1) inhibitor, and an Oct4-activating compound.
- one or more small molecules include a combination of a histone deacetylase inhibitor VPA (V), a GSK3 ⁇ inhibitor CHIR99021 (C), a TGF- ⁇ inhibitor 616452 (6), A-83-01 (A), or SB-431542 (S), a lysine specific histone demethylase 1 (LSD1) inhibitor tranylcypromine (T), and an Oct4-activating compound OAC1 (0).
- the combination of the small molecules is “VC6TO” “VCATO” or “VCSTO,” which includes the compounds disclosed herein.
- the combination comprises at least one small molecule that is a TGF- ⁇ inhibitor.
- this disclosure relates to a method of preventing or treating a neurodegenerative disease or a neurological disorder associated with astrocyte dysfunction in a subject.
- the method entails reprogramming or converting somatic tissue or cells into astrocytes or astroglial progenitor cells by contacting the somatic tissue or cells with one or more small molecule compounds as disclosed herein, and transplanting the astrocytes or astroglial progenitor cells into the brain of the subject suffering from the neurodegenerative disease or neurological disorder.
- the neurodegenerative diseases or neurological disorders associated with astrocyte dysfunction include, for example, Alzheimer's disease, Alexander disease, Parkinson's disease, Huntington disease, amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), epilepsy, stroke and cerebral ischemia.
- ALS amyotrophic lateral sclerosis
- MS multiple sclerosis
- epilepsy stroke and cerebral ischemia.
- this disclosure relates to a combination of small molecule compounds which induces or promotes reprogramming or converting somatic tissue or cells into astrocytes or astroglial progenitor cells.
- the small molecule is a TGF- ⁇ inhibitor, including but not limited to TGF- ⁇ inhibitor 616452, A-83-01, SB-431542, SD-208, LY 2109761, GW 788388, LDN-212854, A 77-01, LY2157299, K02288, ML347, and SB-505124 hydrochloride.
- two or more small molecules are used.
- a TGF- ⁇ inhibitor can be used in combination with one or more of a histone deacetylase inhibitor, a GSK3 ⁇ inhibitor, a lysine specific histone demethylase 1 (LSD1) inhibitor, and an Oct4-activating compound.
- one or more small molecules include a combination of a histone deacetylase inhibitor VPA (V), a GSK3 ⁇ inhibitor CHIR99021 (C), a TGF- ⁇ inhibitor 616452 (6), SB-431542 (S), or A-83-01 (A), a lysine specific histone demethylase 1 (LSD1) inhibitor tranylcypromine (T), and an Oct4-activating compound OAC1.
- the combination of the small molecules is “VC6TO” “VCATO” or “VCSTO,” which includes the compounds disclosed herein.
- the combination comprises at least one small molecule that is a TGF- ⁇ inhibitor.
- this disclosure relates to a composition comprising a combination of small molecules, wherein the combination induces or promotes reprogramming or converting somatic tissue or cells into astrocytes or astroglial progenitor cells.
- the small molecule is a TGF- ⁇ inhibitor, including but not limited to TGF- ⁇ inhibitor 616452, A-83-01, SB-431542, SD-208, LY 2109761, GW 788388, LDN-212854, A 77-01, LY2157299, K02288, ML347, and SB-505124 hydrochloride.
- two or more small molecules are used.
- a TGF- ⁇ inhibitor can be used in combination with one or more of a histone deacetylase inhibitor, a GSK3 ⁇ inhibitor, a lysine specific histone demethylase 1 (LSD1) inhibitor, and an Oct4-activating compound.
- one or more small molecules include a combination of a histone deacetylase inhibitor VPA (V), a GSK3 ⁇ inhibitor CHIR99021 (C), a TGF- ⁇ inhibitor 616452 (6), SB-431542 (S), or A-83-01 (A), a lysine specific histone demethylase 1 (LSD1) inhibitor tranylcypromine (T), and an Oct4-activating compound OAC1.
- the combination of the small molecules is “VC6TO” “VCATO” or “VCSTO,” which includes the compounds disclosed herein.
- the combination comprises at least one small molecule that is a TGF- ⁇ inhibitor.
- FIGS. 1A-1C illustrate direct reprogramming MEF into astrocyte-like cells.
- FIG. 1A shows that VC6TO induced OG2 MEF into cells with astrocyte-like morphology.
- Oct4 promoter driven-GFP reporter fluorescence and phase contrast images of OG2 MEF before (DO) and after 25 days of VC6TO treatment (D25). No induction of Oct4-GFP reporter was detected. Arrows indicate astrocyte-like cells. Scale bar: 100 ⁇ m.
- FIG. 1B shows no contamination of neural lineage cells in MEF preparation.
- MEFs were stained for neural progenitor markers SOX1 and PAX6, neuronal markers TUJ1 and MAP2, astrocytes markers GFAP and S100 ⁇ , and oligodendrocyte progenitor cell markers NG2 and OLIG2. No staining with these markers was detected. Nuclei Dapi staining is shown in blue. Scale bar, 100 ⁇ m.
- FIG. 1C shows FACS analysis showing 99.6% Fsp1+ cells in MEF. For all quantifications in the figures (unless otherwise specified), error bars are sd of the mean, *p ⁇ 0.05, **p ⁇ 0.01, ***p ⁇ 0.001.
- FIGS. 2A-2E also illustrate direct reprogramming MEF into astrocyte-like cells by VC6TO.
- FIG. 2A shows the scheme of MEF preparation.
- FIG. 2B shows the scheme of astrocytic reprogramming with compound treatment.
- MEFM MEF medium; iAM: induced astrocyte medium; AM: astrocyte medium.
- FIG. 2C shows immunostaining for GFAP and S100 ⁇ in cells derived from MEFs treated with DMSO or VC6TO for 25 days. Nuclei were counter-stained with Dapi. Scale bar, 100 ⁇ m.
- FIGS. 3A-3H illustrate that a TGF ⁇ inhibitor is critical for astrocytic reprogramming.
- FIGS. 3A, 3C, 3E and 3G show immunostaining for GFAP in cells derived from MEFs treated with DMSO control or different compound combinations for 25 days. Nuclei were counter-stained with Dapi. Scale bar, 100 ⁇ m.
- FIGS. 4A-4D illustrate that the treatment with VCSTO inhibited TGF ⁇ target genes.
- FIG. 4A shows immunostaining for GFAP in cells reprogrammed from MEFs treated with VCSTO at different concentrations of S (SB-431542). Scale bar, 100 ⁇ m.
- FIG. 4C shows that treatment with VCSTO exerted no cellular toxicity. MEFs were treated with DMSO or VCSTO with increasing concentrations of S. Cell toxicity was determined by counting live cells 1 week or 2 weeks after vehicle or compound treatment.
- FIGS. 5A-5C illustrate astrocytic reprogramming by VCSTO in tail tip fibroblasts.
- FIG. 5A shows immunostaining for GFAP and S100 ⁇ in cells generated from tail tip fibroblasts (TTFs) treated with VCSTO for 25 days. Nuclei Dapi staining is shown in blue in the merged image. Scale bar, 50 ⁇ m.
- FIGS. 6A-6I illustrate expression of astrocytic markers from VCSTO-induced cells.
- FIGS. 6A-6C show immunostaining for GFAP and S1008 (6A), GFAP and ALDH1L1 (6B), GFAP and visualizing GFAP-GFP ( 6 C) in VCSTO-induced cells. Nuclei Dapi staining (blue) is included in the merged images. Scale bar, 50 ⁇ m.
- MEF from GFAP-GFP mice were induced by VCSTO.
- FIG. 6E shows bisulfite sequencing the Gfap promoter region in MEF, iA and mouse primary astrocytes (pA). Open and closed circles indicate unmethylated and methylated CpGs, respectively.
- FIG. 6F shows immunostaining for GFAP in cells treated with VCSTO for 10, 15, 20 and 25 days. Scale bar, 100 ⁇ m.
- FIG. 6G shows the percentage of GFAP-positive cells in cells treated with VCSTO for different days.
- FIG. 6I shows RT-PCR of pluripotency markers, Oct4 and Nanog, and neural progenitor markers, Sox1 and Pax6, during the time course of VCSTO treatment.
- RNA from mouse embryonic stem cells (ESC) and neural progenitor cells (NPC) was included as positive controls.
- FIGS. 7A-7G illustrate genomic-wide transcriptional profiling of VCSTO-induced astrocytes.
- FIG. 7A shows heatmap presentation of microarray analysis of MEFs, VCSTO-induced astrocytes (iA) and mouse primary astrocytes (pA). Genes upregulated in iA and pA, compared to MEFs, are shown in red, whereas genes downregulated in iA and pA, compared to MEFs, are shown in blue.
- FIG. 7B gene ontology (GO) terms for genes upregulated in both iA and pA, relative to MEFs, are shown in red, whereas GO terms associated with genes downregulated in iA and pA are shown in blue.
- GO gene ontology
- FIG. 7C shows heatmap presentation of a selected set of fibroblast-related genes (the upper 4 genes) and astrocyte-related genes (the lower 4 genes).
- FIGS. 7D and 7E show real time PCR validation of the expression of 4 fibroblast-associated genes ( 7 D) and 4 astrocyte-associated genes ( 7 E).
- the expression in MEFs was defined as 1.
- n 3 experimental repeats.
- FIG. 7F shows schematic presentation of different regions of the brain.
- FIG. 7G shows relative expression of regional subtype markers in iA measured by real time PCR.
- FB forebrain
- HB hindbrain
- DB dorsal brain
- VB ventral brain.
- n 3 experimental repeats.
- FIGS. 8A-8E illustrate gene expression analysis of VCSTO-induced astrocytes.
- FIG. 8A shows hierarchical clustering of induced astrocytes (iA), primary astrocytes (pA) and MEF based on all the probe sets in microarray data.
- FIG. 8B shows Pearson's correlation analysis of iA, pA, and MEF.
- FIGS. 8C and 8D show RT-PCR analysis of 3 fibroblast genes ( 8 C) and 3 astrocyte marker genes ( 8 D) in MEF, iA and pA. The expression in MEF was defined as 1.
- FIG. 8E shows relative expression of regional subtype markers in iA measured by real time PCR.
- FB forebrain
- HB hindbrain
- DB dorsal brain
- FIGS. 9A-9I show that compound-induced astrocytes are functional.
- FIG. 9A shows immunostaining mouse primary cortical neurons for Map2 and Synapsin after co-culturing with MEF, induced astrocytes (iA), and mouse primary astrocytes (pA) for 5 days. Scale bar, 50 ⁇ m.
- FIG. 9C shows increased Map2+ Synapsin+ puncta in neurons co-cultured with iA and pA, relative to co-culture with MEF. Scale bar, 10 ⁇ m.
- FIG. 9A shows immunostaining mouse primary cortical neurons for Map2 and Synapsin after co-culturing with MEF, induced astrocytes (iA), and mouse primary astrocytes (pA) for 5 days. Scale bar, 50 ⁇ m.
- FIG. 9B shows quantification
- FIG. 9F shows calcium signal change in response to glutamate stimulation shown by calcium reporter fluorescent dye intensity change ( ⁇ F/F 0 ) over time (second, s) in iA. Scale bar, 100 ⁇ m.
- FIG. 9G shows lack of calcium spikes after glutamate stimulation in MEF.
- FIG. 9H shows calcium spikes after glutamate stimulation in pA.
- FIG. 10 illustrates Sholl analysis of neurite complexity in co-cultured neurons. Neurons were co-cultured with MEF, induced astrocytes (iA), or mouse primary astrocytes (pA), respectively. Errors bars are sd of the mean.
- FIGS. 11A-11D illustrate VCSTO-induced astrocytes survived and maintained astrocytic marker expression in vivo.
- FIG. 11A shows timeline of cell transplantation and brain harvest.
- FIG. 11B shows two examples of GFP-labeled VCSTO-induced astrocytes (iA) in grafted brains that stained positive for both GFP and GFAP. The endogenous astrocytes are shown as GFP-negative but GFAP-positive. Scale bar, 25 ⁇ m.
- FIG. 11C shows higher magnification images of individual GFP and GFAP double positive cells that are indicated by arrows in panel b. Scale bar, 10 ⁇ m.
- FIG. 11D shows that MEF failed to survive in transplanted brains. MEF were labeled by GFP and transplanted into brains of neonatal immunodeficient mice. No GFP signal was detected in various regions of MEF-transplanted brains two weeks after transplantation. Scale bar, 25 ⁇ m.
- FIGS. 12A-12E illustrate recapitulating GFAP protein aggregates in VCSTO-induced astrocytes (iA) transfected with an AxD mutant GFAP.
- FIG. 12A shows transfection of the R239C AxD mutant GFAP-GFP to iA induced GFAP protein aggregates and ⁇ -crystallin expression.
- iA transfected with the WT and AxD GFAP-GFP were immunostained for GFAP and ⁇ -crystallin. The transfected cells are indicated by GFP.
- Nuclei Dapi staining (blue) is included in the merged images. Scale bar, 10 ⁇ m.
- FIG. 12A shows transfection of the R239C AxD mutant GFAP-GFP to iA induced GFAP protein aggregates and ⁇ -crystallin expression.
- iA transfected with the WT and AxD GFAP-GFP were immunostained for GFAP and ⁇ -c
- FIG. 12B shows that ceftriaxone treatment reduced GFAP protein aggregates in iA transfected with the AxD mutant GFAP-GFP.
- iA transfected with the AxD GFAP-GFP were treated with ceftriaxone (+Cef) or vehicle control ( ⁇ Cef), and stained for GFAP and S1008.
- Scale bar 10 ⁇ m.
- FIG. 12D shows that ceftriaxone treatment had no effect on GFAP protein aggregates in MEF.
- MEF transduced with the AxD GFAP-GFP were treated with ceftriaxone (+Cef) or vehicle control ( ⁇ Cef).
- the percentage of MEF that contain the GFAP-GFP aggregates remained the same in the absence or presence of ceftriaxone treatment.
- n 600 to 900 cells.
- FIG. 12E shows reduced glutamate uptake in iA tranduced with AxD mutant GFAP, compared to iA transduced with WT GFAP.
- n 3 experimental repeats. Error bars are sd of the mean, **p ⁇ 0.01 by Student's t-test.
- FIGS. 13A-13J illustrate reprogramming human fibroblasts into astrocytic cells by VCSTO.
- FIG. 13A shows immunostaining for S100 ⁇ in cells derived from human fibroblasts (SCC058, for panels 13 A to 13 E) treated with DMSO or VCSTO. Nuclei were counter-stained with Dapi. Scale bar, 100 ⁇ m for panels 13 A and 13 B.
- FIG. 13B shows immunostaining for S100 ⁇ or GFAP in cells derived from human fibroblasts treated with DMSO or VCSTO, followed by CNTF treatment.
- FIG. 13A shows immunostaining for S100 ⁇ in cells derived from human fibroblasts (SCC058, for panels 13 A to 13 E) treated with DMSO or VCSTO. Nuclei were counter-stained with Dapi. Scale bar, 100 ⁇ m for panels
- FIG. 13D show expression of astrocyte marker genes in VCSTO-induced human astrocytes (iA) as measured by real time PCR.
- the expression in human fibroblasts (hF) was defined as 1.
- n 4 experimental repeats.
- FIG. 13E shows substantially elevated glutamate uptake in iA relative to parental fibroblasts (hF).
- n 3 experimental repeats.
- FIG. 13F shows calcium imaging analysis of human induced astrocytes.
- Human induced astrocytes (iA) exhibited calcium signal change in response to glutamate stimulation, similar to human iPSC-derived astrocytes (hA). Lack of calcium spikes after glutamate stimulation in human fibroblasts (hF) was included as a negative control.
- FIG. 13G shows immunostaining for S100 ⁇ and GFAP in cells derived from human adult fibroblasts (AG14048, for panels 13 G to 13 J) treated with DMSO or VCSTO. Nuclei were counter-stained with Dapi. Scale bar, 100 ⁇ m.
- iPSCs induced pluripotent stem cells
- neural stem cells Kim et al., 2011; Han et al., 2012; Lujan et al., 2012
- neurons Vierbuchen et al., 2010; Caiazzo et al., 2011; Pang et al., 2011; Yoo et al., 2011
- oligodendrocytes Najm et al., 2013; Yang et al., 2013.
- Direct reprogramming of somatic cells into astrocytes using defined transcription factors has been reported (Caiazzo et al., 2015).
- the conventional technologies have certain restrictions.
- the process of inducing human iPSCs from somatic cells such as fibroblasts and then converting human iPSCs to astrocytes is a lengthy process and takes about 90 days or even longer.
- Direct reprogramming of somatic cells into astrocytes using certain transcription factors involves introducing transgenes and therefore leaves “footprint” of residual transgenes or other contaminants.
- the technology and methods disclosed herein solves the problems in the art by direct reprogramming or converting somatic cells such as fibroblasts into astrocytes using one or more small molecules without the requirement of producing any intermediate stem cells and without introducing any transgene or contaminant.
- the process of direct reprogramming disclosed herein takes much shorter time, e.g., less than or about 30 days, than the conventional technology, e.g., 90 days.
- mouse or human fibroblasts were reprogrammed into functional astrocytes, which possess the ability to promote neuronal maturation and synaptic formation, uptake glutamate, and induce calcium signal in response to glutamate stimulation.
- astrocytes include neural stem cells, neurons, and oligodendrocytes.
- Induced neurons can be developed into useful tools for modeling a variety of neurological diseases affecting neurons (Lujan and Wernig, 2012).
- induced neuronal cells would have limitations for modeling disease affecting astrocytes.
- astrocytes could be derived from iPSCs, the differentiation process is lengthy. These limitations could be overcome by inducing astrocytes directly from fibroblasts in a relatively short period of time as described in detail in this disclosure.
- TGF ⁇ inhibitor alone was able to induce GFAP-positive cells from MEFs, providing an example that one single compound is able to induce the conversion of one somatic cell type to another.
- astrocytes were derived from MEFs at an efficiency of 0.004% to 2% in up to 70 days.
- Disclosed herein is a direct reprogramming method that does not go through iPSC or iNSC/iNPC intermediate state.
- Astrocytes can be converted from MEFs at an efficiency of about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, or about 100%, in a shorter period of time, such as 20 to 25 days, by the method disclosed herein. Therefore, the direct chemical reprogramming method described in this disclosure provides a more rapid and efficient way to derive astrocytes from fibroblasts.
- the chemically induced astrocytes can be used to model diseases with astrocyte dysfunction.
- the working examples demonstrate that when an AxD mutant GFAP was transfected into induced astrocytes, the phenotype of GFAP protein aggregation observed in AxD patient astrocytes was recapitulated. Moreover, these protein aggregates were responsive to ceftriaxone treatment. Therefore, the chemically induced astrocytes disclosed herein can be used as a tool to study neurodevelopment in glial context, and to model a variety of neurological diseases with astrocyte dysfunction. Additionally, induced astrocytes containing disease-causing mutations can be produced by the methods disclosed herein. The induced astrocytes, as well as induced astrocytes containing mutations can be used for detecting, preventing or treating astrocyte-associated diseases.
- the somatic tissue or cells to be converted into astrocytes or astroglial progenitor cells are autologous tissue or cells.
- the somatic tissue or cells that can be converted to astrocytes or astroglial progenitor cells include fibroblasts, urinary cells, blood cells, adipocytes, keratinocytes, and dental pulp cells.
- the method includes contacting the somatic tissue or cells with one or more small molecules, wherein the one or more small molecules include at least one TGF- ⁇ inhibitor.
- the TGF- ⁇ inhibitor is an inhibitor of TGF- ⁇ R1 (ALK5).
- the somatic tissue or cells are cultured in the presence of the one or more small molecules under a suitable condition for a period of time sufficient for the somatic tissue or cells to be converted into astrocytes or astroglial progenitor cells.
- a single small molecule is sufficient to induce the conversion to astrocytes or astroglial progenitor cells, and the small molecule is a TGF- ⁇ inhibitor.
- two or more small molecules are used, and at least one small molecule is a TGF- ⁇ inhibitor.
- TGF- ⁇ inhibitors Small molecule TGF- ⁇ inhibitors are known in the art (Calone 2012) and many are commercially available. Some examples of TGF- ⁇ inhibitors include but are not limited to 616452, A-83-01, SB-431542, SD-208, LY 2109761, GW 788388, LDN-212854, A 77-01, LY2157299, K02288, ML347, and SB-505124 hydrochloride, as shown in Table 1 below.
- two or more small molecules are used.
- a histone deacetylase (HDAC) inhibitor In combination with a TGF- ⁇ inhibitor, at least one of a histone deacetylase (HDAC) inhibitor, a GSK3 ⁇ inhibitor, a lysine specific histone demethylase 1 (LSD1) inhibitor, and an Oct4-activating compound can be used.
- HDAC histone deacetylase
- GSK3 ⁇ inhibitor GSK3 ⁇ inhibitor
- LSD1 lysine specific histone demethylase 1
- Oct4-activating compound Some examples of each category are provided in the tables below.
- GSK3 ⁇ Inhibitors Small Molecule Chemical Structure
- GSK-3 ⁇ Inhibitor XII GSK-3 Inhibitor XVI 10Z-Hymenialdisine CHIR-98014
- GSK-3 ⁇ Inhibitor VI GSK-3 ⁇ Inhibitor I GSK-3 ⁇ Inhibitor VII 3F8
- GSK-3 Inhibitor II GSK-3 ⁇ Inhibitor VIII
- OAC compounds have the following structure with each substituent group listed in Table 5:
- Table 5 shows the Oct4-activating activity of compound Cl and its structural analogs. Compounds that induce Oct4-luc 1.8-fold or more were classified as being “active”, and molecules that induce Oct4-luc less than 1.8-fold were indicated as being “inactive”. ND: not determined.
- TGF- ⁇ inhibitor is used in combination with a histone deacetylase inhibitor, or in combination with a histone deacetylase inhibitor and a GSK3 ⁇ inhibitor.
- Other examples include the combination of a TGF- ⁇ inhibitor with a histone deacetylase inhibitor and a GSK3 ⁇ inhibitor, a TGF- ⁇ inhibitor with a histone deacetylase inhibitor and an Oct4-activating compound, or a TGF- ⁇ inhibitor with a LSD1 inhibitor and an Oct4-activating compound.
- TGF- ⁇ inhibitor with different categories of at least one of a histone deacetylase inhibitor, a GSK3 ⁇ inhibitor, a lysine specific histone demethylase 1 (LSD1) inhibitor, and an Oct4-activating compound are for illustration purposes only and are not intended to limit the scope of this invention.
- one or more small molecules include a combination of a histone deacetylase inhibitor VPA (V), a GSK3 ⁇ inhibitor CHIR99021 (C), a TGF- ⁇ inhibitor 616452 (6), A-83-01 (A) or SB-431542 (S), a lysine specific histone demethylase LSD1 inhibitor tranylcypromine (T), and an Oct4-activating compound OAC1 (0).
- the combination of the small molecules is “VC6TO,” “VCATO,” or “VCSTO,” which includes the compounds disclosed herein.
- the combination comprises at least one small molecule that is a TGF- ⁇ inhibitor.
- the concentration of a TGF- ⁇ inhibitor is within a range between 1 ⁇ M and 100 ⁇ M, between 2 ⁇ M and 50 ⁇ M, between 3 ⁇ M and 30 ⁇ M, between 5 ⁇ M and 10 ⁇ M.
- the concentration of a TGF- ⁇ inhibitor is about 1 ⁇ M, about 2 ⁇ M, about 3 ⁇ M, about 4 ⁇ M, about 5 ⁇ M, about 6 ⁇ M, about 7 ⁇ M, about 8 ⁇ M, about 9 ⁇ M, about 10 ⁇ M, about 11 ⁇ M, about 12 ⁇ M, about 13 ⁇ M, about 14 ⁇ M, about 15 ⁇ M, about 20 ⁇ M, about 25 ⁇ M, about 30 ⁇ M, about 35 ⁇ M, about 40 ⁇ M, about 45 ⁇ M, or about 50 ⁇ M, without causing significant cytotoxicity.
- the somatic tissue or cells Upon culturing the somatic tissue or cells in the presence of one or more small molecules for a period of between 7 days and 90 days, between 10 days and 60 days, between 15 days and 45 days or between 20 days and 30 days, the somatic tissue or cells are reprogrammed or converted into functional astrocytes or astroglial progenitor cells. It is within the purview of one skilled in the art to adjust the culturing period to optimize the percentage of conversion, for example, by choosing different combinations of the small molecules.
- the induced astrocytes or astroglial progenitor cells contain either or both of anterior and posterior subtypes.
- the induced astrocytes or astroglial progenitor cells can also contain either or both of dorsal and ventral subtypes.
- the one or more small molecules disclosed herein can reprogram or convert somatic tissue or cells to astrocytes or astroglial progenitor cells.
- the mouse or human induced astrocytes resemble primary astrocytes in astrocytic gene expression and epigenetic status, and exhibit functional properties in promoting neuronal maturation, glutamate uptake and calcium signaling. Moreover, these cells can recapitulate Alexander disease phenotype of protein aggregation when expressing Gfap with a disease-causing mutation.
- the same compounds can also reprogram human fibroblasts into astroglial progenitor cells that can be further matured into functional astrocytes. Therefore, these induced astrocytes can be used in methods for preventing or treating neurodevelopmental disorders or neurological diseases that are associated with dysfunction of astrocytes. These induced astrocytes can also be used to screen and test candidate drugs for these diseases.
- this disclosure relates to a method of preventing or treating a neurodegenerative disease or a neurological disorder associated with astrocyte dysfunction in a subject.
- the method entails reprogramming or converting somatic tissue or cells into astrocytes or astroglial progenitor cells using one or more small molecule compounds as disclosed herein, and transplanting the astrocytes or astroglial progenitor cells into the brain of the subject suffering from the neurodegenerative disease or neurological disorder.
- the somatic tissue or cells are autologous tissue or cells isolated from the subject to be treated.
- the somatic tissue or cells that can be converted to astrocytes or astroglial progenitor cells include fibroblasts, urinary cells, and blood cells.
- the neurodegenerative diseases or neurological disorders associated with astrocyte dysfunction include, for example, Alzheimer's disease, Alexander disease, Parkinson's disease, Huntington disease, amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), epilepsy, stroke and cerebral ischemia.
- treating refers to preventing the condition, slowing the onset or rate of development of the condition, reducing the risk of developing the condition, preventing or delaying the development of symptoms associated with the condition, reducing or ending symptoms associated with the condition, generating a complete or partial regression of the condition, or some combination thereof.
- treating a condition means that the condition is cured without recurrence.
- MEFs and TTFs were derived from E13.5 embryos of Oct4-GFP transgenic (OG2) mice (Szabo et al., 2002), wild type or GFAP-GFP transgenic mice (Jackson Laboratory) (Zhuo et al., 1997). These cells were cultured in MEF medium containing DMEM, 10% FBS, 0.1 mM nonessential amino acids, and 2 mM L-glutamine. Mouse primary astrocytes were isolated from P1-2 pups following published protocol (Schildge et al., 2013) and cultured in DMEM containing 10% FBS.
- MEFs were plated on 6-well or 12-well plates at a cell density of 3 ⁇ 10 3 cells/cm 2 .
- Cells were cultured in MEF medium for 24 hr, then changed to mouse induced astrocyte medium (iAM) containing knock-out DMEM with 10% knock-out serum replacer, 10% FBS, 2 mM L-glutamine, 0.1 mM NEAA, 0.1 mM ⁇ -mercaptoethanol, and 100 ng/ml FGF.
- iAM mouse induced astrocyte medium
- valproaic acid Stemgent
- 3 ⁇ M CHIR99021(D&C chemicals) 3 ⁇ M CHIR99021(D&C chemicals)
- 10 ⁇ M SB-431542 D&C chemicals
- 10 ⁇ M Tranylcypromine Stemgent
- 1 ⁇ M OAC1(Li et al., 2012) 10 days, re-plated onto Matrigel-coated plates (BD Biosciences) and continued with compound treatment for another 15 days.
- Cells were then switched to mouse astrocyte medium (AM) containing DMEM with 10% heat-inactivated FBS.
- AM mouse astrocyte medium
- GFAP-GFP positive iAs were sorted using the FACSAria III cell sorter (BD Bioscience). Gene expression profiling was performed using Mouse Gene 2.0 ST array (Affymetrix). Microarray data analysis was performed using Partek® Genomics SuiteTM (Partek, Inc.). Expression values were Robust Multi-array Average (RMA) normalized (Irizarry et al., 2003). Fold-change values represent the linear ratio between signal intensities when the ratio value is greater than 1 and -1/ratio when the ratio is less than 1. Genes were defined as differentially expressed if they showed a fold-change value >1.5.
- Heatmaps to visualize differentially expressed genes were produced in Partek using Euclidian distance for hierarchical clustering of standardized expression values. Gene Ontology enrichment was performed for functional enrichment of commonly affected genes, with p-values calculated via Fisher's exact test. Microarray data have been deposited to NCBI's GEO under accession number GSE81927.
- Astrocyte-neuron co-cultures Mouse cortical neurons were isolated from E13.5 mouse embryo and cultured in neuronal culture media (neurobasal, 1X B27, 2 mM L-glutamine) alone or directly on a layer of induced astrocytes (iA), mouse primary astrocytes (pA) or MEF for 5 days. Mouse neurons, iA, pA or MEFs were plated at the same density of 10,000 cells/cm 2 . The co-cultured cells were stained for MAP2 and Synapsin. The Synapsin+puncta along the MAP2+neurites were expressed as the number of puncta per 50 ⁇ m neurite length.
- Induced astrocytes labeled by GFP-expressing lentivirus were dissociated using trypsin-EDTA and resuspended in medium at 100,000 cells/ ⁇ l density and kept on ice.
- Two ⁇ l cell suspensions were injected 1 mm from the midline between the Bregma and Lambda and 1 mm deep into the anterior lateral ventricles of immunodeficient neonatal NSG mice. After 6 weeks, mice were euthanized and perfused with 4% PFA for 5 min. Brain tissues were harvested for immunostaining. All animal work was performed under the IACUC protocol approved by the City of Hope IACUC Committee.
- Genomic DNAs were isolated from MEF, FACS-sorted induced astrocytes and mouse primary astrocytes using a Genomic DNA Purification Kit (Qiagen). Bisulfite conversion of genomic DNAs was carried out using the EZ DNA Methylation-Gold Kit (Zymo Research). The bisulfite-modified DNA was then used as a template for PCR to amplify the promoter region of Gfap. The amplified products were cloned into the pCR2.1-TOPO cloning vector (Invitrogen), and 10 randomly selected clones were sequenced using T7 or M13R primers.
- Glutamate uptake assay The glutamate uptake was measured using the Glutamate Assay Kit (BioVision). Induced astrocytes were plated at a concentration of 2 ⁇ 10 4 cells per well in a 24-well plate. 100 ⁇ M L-glutamate was added to each well. After incubation for 6 h, the glutamate concentration in the media was measured and presented as nmol of glutamate per mg of total proteins.
- Human fibroblasts were purchased from Millipore (SCC058) or Coriell (AG14048) and tested for lack of mycoplasm contamination. Human fibroblasts were seeded onto 6-well plates at the density of 10 4 cells/cm 2 and cultured in either FibroGRO complete medium (for SCC058) or Eagle's MEM with 15% non-inactivated fetal bovine serum (for AG14048) for 24 hr, then switched to induced astrocyte medium containing DMEM/F12 with 2 mM L-glutamine, 0.1 mM NEAA, 1xN2, 1xB27 and 100 ng/ml FGF.
- FibroGRO complete medium for SCC058
- Eagle's MEM with 15% non-inactivated fetal bovine serum
- VCSTO compounds including 500 nM VPA (Stemgent), 3 ⁇ M CHIR99021 (D&C chemicals), 10 ⁇ M SB-431542 (D&C chemicals), 10 ⁇ M Tranylcypromine (Stemgent), and 1 ⁇ M OAC1 (Li et al., 2012) for 20 days, re-plated onto Matrigel-coated plates and continued with compound treatment for another 20 days. Cells were then treated with 10 ng/ml CNTF for another 6 days. For AG14048, cells were treated with VCSTO compounds at the same concentration as described above for 30 days, then treated with VCSTO together with 10 ng/ml CNTF for another 10 days.
- FSP1 FACS analysis MEFs were stained by FSP1 antibody (Millipore, ABF32). FACS analysis was performed on Flow Cytometry Analyzers BD Fortessa (BD Bioscience).
- Example 2 A compound cocktail induced the conversion from MEFs to astrocyte-like cells
- a compound combination including the histone deacetylase inhibitor VPA (V), the GSK3 ⁇ inhibitor CHIR99021 (C), the TGF ⁇ inhibitor 616452 (6), the lysine specific histone demethylase LSD1 inhibitor Tranylcypromine (T), the cyclic AMP inducer forskolin (F), and a histone methylation inhibitor DZNep (Z) was used to reprogram mouse embryonic fibroblasts (MEFs) into iPSCs (Hou et al., 2013). In this chemical cocktail, compounds F and Z were used together to induce the expression of Oct4, a factor critical for reprogramming.
- the VC6TO cocktail was tested to see if it could reprogram MEFs into astrocytes. Any neural tissues was excluded from the MEF preparation ( FIG. 2A ) as described (Vierbuchen et al., 2010). Immunostaining MEFs with various neural lineage markers revealed no contamination of neural progenitor cells, neurons, astrocyes, and oligodendrocyte progenitor cells ( FIG. 1B ), instead 99.6% cells expressed the fibroblast marker FSP1 ( FIG. 1C ). These MEFs were treated with VC6TO and cultured in induced astrocyte medium ( FIG. 2B ).
- GFAP glial fibrillary acidic protein
- Example 3 A TGF ⁇ inhibitor was critical for astrocytic conversion
- TGF ⁇ transforming growth factor ⁇ (TGF ⁇ ) receptor 1 kinase inhibitor
- other inhibitors of TGF ⁇ receptor 1 were tested for inducing astrocytic reprogramming together with VCTO.
- Compound A-83-01 (A) or SB-431542 (S) two well-characterized inhibitors of TGF ⁇ receptor 1 (Inman et al., 2002; Tojo et al., 2005) was tested.
- Treating MEFs with either the combination of VCTO with A (VCATO) or VCTO with S (VCSTO) induced a substantial increase in GFAP-positive cells with astrocyte morphology ( FIG. 3C, 3D ).
- VCATO and VCSTO induced more GFAP-positive cells than the initial VC6TO combination ( FIG. 3B-3D ), with the highest conversion efficiency observed with VCSTO, which induced 38% GFAP-positive cells at day 25 after compound treatment. The rest of the study was focused on VCSTO-induced reprogramming.
- TGF ⁇ receptor 1 Since S is an inhibitor of TGF ⁇ receptor 1 (Inman et al., 2002), whether the TGF ⁇ signaling is suppressed by VCSTO treatment was tested. After 24 hr VCSTO treatment of MEFs, dramatic inhibition of gene expression was observed for a set of TGF ⁇ downstream effectors ( FIG. 4D ), including Atf4, Col1a1, decorin (Dcn), Gadd45b, Ifrd1, p21, p27, Tgfb1i1, Tgfbi, and Tsc22d1, consistent with the role of S in inhibiting TGF ⁇ signaling. These results indicate that a TGF ⁇ inhibitor is critical for converting fibroblasts into astrocyte-like cells.
- mice were treated with VCSTO compounds. Twenty-five days after VCSTO treatment, GFAP-positive and S100 ⁇ -positive cells with astrocyte morphology were detected ( FIG. 5A ). The percentage of GFAP+S100 ⁇ + cells was similar to that of GFAP+ cells ( FIG. 5A-5C ).
- Example 4 VCSTO-induced cells express astrocytic genes and exhibit epigenetic reprogramming
- VCSTO-reprogrammed cells were indeed astrocytes
- astrocytic marker expression in these cells was first determined. Double staining for GFAP and S100 ⁇ revealed that the VCSTO-induced cells expressed both GFAP and S100 ⁇ ( FIG. 6A ). In addition to GFAP and S100 ⁇ , ALDH1L1 has been identified to be a reliable marker for astrocytes (Barres, 2008). Double staining the VCSTO-reprogrammed cells with GFAP and ALDH1L1 revealed that the compound-induced cells were positive for both of these astrocytic markers ( FIG. 6B ). These results further confirmed the astrocyte identity of the VCSTO-induced cells.
- GFAP-GFP reporter mice Because astrocytes could be visualized by GFP fluorescence in the GFAP-GFP reporter mice (Zhuo et al., 1997), MEFs from these mice were derived and treated with VCSTO to monitor astrocytic conversion. GFAP-GFP-positive cells emerged around day 10 to day 15 after VCSTO treatment. The induced cells were visualized for GFAP-GFP fluorescence and immunostained for GFAP at day 25 after VCSTO treatment. Nearly all GFAP-GFP positive cells were also positive for GFAP immunostaining ( FIG. 6C ).
- VCSTO-reprogrammed cells express high levels of glutamate transporters, predominantly GLT-1 and GLAST (Chaudhry et al., 1995). Aquaporin 4 (AQP4), a member of the aquaporin family of membrane proteins, is also enriched in astrocytes (Simard and Nedergaard, 2004).
- Real time PCR revealed that the VCSTO-reprogrammed cells expressed high levels of Glt-1, Glast, and Aqp4, in addition to the astrocytic markers Gfap, S100 ⁇ , and Aldh1l1 ( FIG. 6D ), further strengthening the conclusion that the VCSTO-reprogrammed cells are astrocytes.
- MEFs were treated with VCSTO for various time periods and immunostaining and RT-PCR were performed at days 10, 15, 20 and 25.
- GFAP-positive cells were seen at day 10 after compound treatment, although the efficiency was low ( FIG. 6F, 6G ).
- FIG. 6F, 6G By day 15, more than 15% GFAP-positive cells were detected.
- the rate of conversion further increased with time.
- GFAP-positive cells reached more than 30% ( FIG. 6F, 6G ).
- increased expression of the astrocytic markers Gfap, S100 ⁇ , and Aldh1l1 was observed along the time course, with the highest induction at day 25 ( FIG. 6H ).
- Genome-wide profiling was performed to compare gene expression pattern of VCSTO-induced astrocytes with that of primary astrocytes and MEFs.
- MEFs were derived from GFAP-GFP reporter mice and treated with VCSTO for 25 days.
- the reprogrammed cells were sorted for GFAP-GFP-positive cells and subjected to DNA microarray analysis, along with primary astrocytes and MEFs.
- a heatmap depicting all probe sets that were differentially expressed by at least 1.5-fold showed that the transcriptional program characteristic of MEFs was globally reprogrammed toward that of astrocytic lineage ( FIG. 7A ).
- Hierarchical clustering revealed that the overall gene expression pattern in induced astrocytes is more similar to that in primary astrocytes than to parent MEFs ( FIG. 8A, 8B ).
- genes up-regulated ( ⁇ 2-fold) in primary astrocytes compared to MEFs 53.9% were also up-regulated in iA; among the genes down-regulated in primary astrocytes relative to MEFs, 68.3% were also down-regulated in iA.
- GO gene ontology
- VCSTO-induced astrocytes contain both anterior and posterior astrocyte subtypes, perhaps with a more abundant subpopulation of posterior astrocytes.
- VCSTO-induced astrocytes are predominantly dorsal, exhibiting robust Pax3 and Trhr expression, but barely detectable Nkx2.1 and Lix1 expression ( FIG. 7G & FIG. 8E ).
- Example 6 VCSTO-induced astrocytes are functional
- induced astrocytes were co-cultured with mouse primary cortical neurons.
- Neuronal maturation was evaluated by immunostaining with a mature neuronal marker, MAP2, at day 5 after co-culture. Both total neurite length and neurite complexity were increased in neurons co-cultured with induced astrocytes or primary astrocytes, compared to that in neurons co-cultured with MEFs ( FIG. 9A, 9B & FIG. 10 ).
- VCSTO-induced astrocytes exhibited glutamate-induced calcium spikes, in a manner similar to primary astrocytes, whereas MEFs did not respond to glutamate stimulation with calcium spikes ( FIG. 9G-I ). These results suggest that induced astrocytes acquire the ability to respond to neurotransmitters through calcium signaling, like primary astrocytes.
- the chemically induced astrocytes are functional astrocytes with the ability to promote neuronal survival and maturation, uptake glutamate and respond to calcium signaling.
- Example 7 VCSTO-induced astrocytes can survive and retain astrocyte identity in vivo
- the VCSTO-induced astrocytes were labeled with a GFP reporter and transplanted into the lateral ventricles of immunodeficient neonatal NOD scid gamma (NSG) mice ( FIG. 11A ).
- NSG immunodeficient neonatal NOD scid gamma mice
- FIG. 11A Six weeks after transplantation, the grafted brains were analyzed by immunostaining.
- the GFP-positive grafted cells survived 6-week engraftment and continued to express GFAP in the brain ( FIG. 11B, 11C ).
- the control MEFs were not able to survive the engraftment in the transplanted brains ( FIG. 11D ).
- Example 8 Compound-induced astrocytes can be used to model neurological disease
- AxD is a neurological disease with astrocyte dysfunction and is caused by genetic mutation of the GFAP gene (Messing et al., 2012). Expression of AxD mutant GFAP induces the expression of ⁇ -crystallin, a small heat shock protein, and the formation of protein aggregates containing GFAP and ⁇ -crystallin in astrocytes (Messing et al., 2012). The compound-induced astrocytes were tested to see if they could be used to model AxD.
- the ⁇ -lactam antibiotic ceftriaxone has been shown to facilitate the elimination of AxD mutant GFAP protein aggregates in primary astrocytes (Bachetti et al., 2010).
- VCSTO-induced astrocytes transfected with the AxD mutant GFAP were treated with ceftriaxone.
- Substantial elimination of GFAP protein aggregates was detected in ceftriaxone-treated cells, compared to vehicle control-treated cells ( FIG. 12B, 12C ).
- MEFs transduced with the AxD mutant GFAP also exhibited GFAP protein aggregates, the fibroblast aggregates were not responsive to ceftriaxone treatment ( FIG. 12D ).
- Example 9 VCSTO could induce astrocytic conversion from human fibrobasts
- human foreskin fibroblasts were treated with VCSTO compounds. Forty days after compound treatment, a large number of cells with astroglial progenitor-like morphology were observed. Because S100 ⁇ is a marker for human astroglial progenitor cells and astrocytes, the VCSTO-treated cells were stained for S100 ⁇ and it was found that more than 30% of cells were S100 ⁇ + cells, whereas no S100 ⁇ + cells were detected in DMSO-treated cells ( FIG. 13A, 13C ).
- CNTF ciliary neurotrophic factor
- astrocyte marker genes GFAP, S100 ⁇ , AQP4 and EAAT2
- VCSTO-reprogrammed cells iA
- hA human iPSC-derived astrocytes
- the expression level of the astrocytic genes is much lower in DMSO-treated human fibroblasts (hF) ( FIG. 13D ).
- human induced astrocytes exhibited potent glutamate uptake, compared to parental fibroblasts ( FIG. 13E ).
Abstract
Disclosed herein are methods of reprograming autologous tissues or cells into astrocytes or astroglial progenitor cells using one or more small molecule compounds only without any transgenes. Also disclosed are methods of preventing or treating neurodegenerative diseases or neurological disorders associated with dysfunction of astrocytes, such as Alzheimer's Disease, by transplanting the astrocytes or astroglial progenitor cells produced by the methods disclosed herein into the brain of a subject suffering from the neurodegenerative disease or neurological disorder.
Description
- This application is a divisional of U.S. application Ser. No. 16/311,965, filed Dec. 20, 2018, which is a 371 national phase application of International Application No. PCT/US2017/038611, filed Jun. 21, 2017, which claims priority to U.S. Application No. 62/353,214, filed Jun. 22, 2016, which are incorporated herein by reference in their entirety, as if fully set forth herein.
- This invention was made with government support under grant number TR2-01832 and RB4-06277 awarded by California Institute for Regenerative Medicine.
- This application contains a Sequence Listing, which was submitted in ASCII format via EFS-Web, and is hereby incorporated by reference in its entirety. The ASCII copy, created on Mar. 28, 2022, is named SequenceListing.txt and is 14 KB in size.
- Astrocytes are glial cells that are located in all regions of the brain (Molofsky et al., 2012; Verkhratsky et al., 2012). They have long been held as the supporting components in neural tissues (Wang and Bordey, 2008; Sofroniew and Vinters, 2010). However, over the past decades, increasing evidence has established a variety of essential functions for astrocytes in neural development and in the pathogenesis of neurological diseases (Verkhratsky et al., 2012). Astrocytes play a critical role in neuronal maturation, synapse formation and plasticity, and glutamate clearance to reduce excitotoxicity (Banker, 1980; Song et al., 2002; Hama et al., 2004; Eroglu and Barres, 2010). Astrocyte dysfunction contributes to many neurodegenerative diseases and is the direct cause for some neurological disorders (Molofsky et al., 2012; Verkhratsky et al., 2012), such as Alexander disease (AxD) (Messing et al., 2012). Despite increasing data revealing new roles for astrocytes, the knowledge on astrocytes remains largely behind what is known about their neuronal counterpart. There is a need in the field to provide functional astrocytes, preferably from autologous tissues or cells, for preventing or treating neurodegenerative diseases or conditions associated with astrocyte dysfunction. The technology and methods disclosed herein satisfy this need.
- In one aspect, this disclosure relates to a method of reprogramming or converting somatic tissue or cells into astrocytes or astroglial progenitor cells by contacting the somatic tissue or cells with one or more small molecules only without introducing any transgenes. In some embodiments, the somatic tissue or cells are autologous tissue or cells. The somatic tissue or cells that can be reprogrammed or converted include but are not limited to fibroblasts, urinary cells, blood cells, adipocytes, keratinocytes, and dental pulp cells. In some embodiments, at least one small molecule is a TGF-β inhibitor, including but not limited to TGF-β inhibitor 616452, A-83-01, SB-431542, SD-208, LY 2109761, GW 788388, LDN-212854, A 77-01, LY2157299, K02288, ML347, and SB-505124 hydrochloride.
- In some embodiments, two or more small molecules are used. For example, a TGF-β inhibitor can be used in combination with one or more of a histone deacetylase inhibitor, a GSK3β inhibitor, a lysine specific histone demethylase 1 (LSD1) inhibitor, and an Oct4-activating compound. In some embodiments, one or more small molecules include a combination of a histone deacetylase inhibitor VPA (V), a GSK3βinhibitor CHIR99021 (C), a TGF-β inhibitor 616452 (6), A-83-01 (A), or SB-431542 (S), a lysine specific histone demethylase 1 (LSD1) inhibitor tranylcypromine (T), and an Oct4-activating compound OAC1 (0). In some embodiments, the combination of the small molecules is “VC6TO” “VCATO” or “VCSTO,” which includes the compounds disclosed herein. In a preferred embodiment, the combination comprises at least one small molecule that is a TGF-β inhibitor.
- In another aspect, this disclosure relates to a method of preventing or treating a neurodegenerative disease or a neurological disorder associated with astrocyte dysfunction in a subject. The method entails reprogramming or converting somatic tissue or cells into astrocytes or astroglial progenitor cells by contacting the somatic tissue or cells with one or more small molecule compounds as disclosed herein, and transplanting the astrocytes or astroglial progenitor cells into the brain of the subject suffering from the neurodegenerative disease or neurological disorder. The neurodegenerative diseases or neurological disorders associated with astrocyte dysfunction include, for example, Alzheimer's disease, Alexander disease, Parkinson's disease, Huntington disease, amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), epilepsy, stroke and cerebral ischemia.
- In a related aspect, this disclosure relates to a combination of small molecule compounds which induces or promotes reprogramming or converting somatic tissue or cells into astrocytes or astroglial progenitor cells. In some embodiments, the small molecule is a TGF-β inhibitor, including but not limited to TGF-β inhibitor 616452, A-83-01, SB-431542, SD-208, LY 2109761, GW 788388, LDN-212854, A 77-01, LY2157299, K02288, ML347, and SB-505124 hydrochloride. In some embodiments, two or more small molecules are used. For example, a TGF-β inhibitor can be used in combination with one or more of a histone deacetylase inhibitor, a GSK3β inhibitor, a lysine specific histone demethylase 1 (LSD1) inhibitor, and an Oct4-activating compound. In some embodiments, one or more small molecules include a combination of a histone deacetylase inhibitor VPA (V), a GSK3β inhibitor CHIR99021 (C), a TGF-βinhibitor 616452 (6), SB-431542 (S), or A-83-01 (A), a lysine specific histone demethylase 1 (LSD1) inhibitor tranylcypromine (T), and an Oct4-activating compound OAC1. In some embodiments, the combination of the small molecules is “VC6TO” “VCATO” or “VCSTO,” which includes the compounds disclosed herein. In a preferred embodiment, the combination comprises at least one small molecule that is a TGF-βinhibitor.
- In yet another aspect, this disclosure relates to a composition comprising a combination of small molecules, wherein the combination induces or promotes reprogramming or converting somatic tissue or cells into astrocytes or astroglial progenitor cells. In some embodiments, the small molecule is a TGF-β inhibitor, including but not limited to TGF-β inhibitor 616452, A-83-01, SB-431542, SD-208, LY 2109761, GW 788388, LDN-212854, A 77-01, LY2157299, K02288, ML347, and SB-505124 hydrochloride. In some embodiments, two or more small molecules are used. For example, a TGF-β inhibitor can be used in combination with one or more of a histone deacetylase inhibitor, a GSK3β inhibitor, a lysine specific histone demethylase 1 (LSD1) inhibitor, and an Oct4-activating compound. In some embodiments, one or more small molecules include a combination of a histone deacetylase inhibitor VPA (V), a GSK3β inhibitor CHIR99021 (C), a TGF-β inhibitor 616452 (6), SB-431542 (S), or A-83-01 (A), a lysine specific histone demethylase 1 (LSD1) inhibitor tranylcypromine (T), and an Oct4-activating compound OAC1. In some embodiments, the combination of the small molecules is “VC6TO” “VCATO” or “VCSTO,” which includes the compounds disclosed herein. In a preferred embodiment, the combination comprises at least one small molecule that is a TGF-β inhibitor.
-
FIGS. 1A-1C illustrate direct reprogramming MEF into astrocyte-like cells.FIG. 1A shows that VC6TO induced OG2 MEF into cells with astrocyte-like morphology. Oct4 promoter driven-GFP reporter fluorescence and phase contrast images of OG2 MEF before (DO) and after 25 days of VC6TO treatment (D25). No induction of Oct4-GFP reporter was detected. Arrows indicate astrocyte-like cells. Scale bar: 100 μm.FIG. 1B shows no contamination of neural lineage cells in MEF preparation. MEFs were stained for neural progenitor markers SOX1 and PAX6, neuronal markers TUJ1 and MAP2, astrocytes markers GFAP and S100β, and oligodendrocyte progenitor cell markers NG2 and OLIG2. No staining with these markers was detected. Nuclei Dapi staining is shown in blue. Scale bar, 100 μm.FIG. 1C shows FACS analysis showing 99.6% Fsp1+ cells in MEF. For all quantifications in the figures (unless otherwise specified), error bars are sd of the mean, *p<0.05, **p<0.01, ***p<0.001. -
FIGS. 2A-2E also illustrate direct reprogramming MEF into astrocyte-like cells by VC6TO.FIG. 2A shows the scheme of MEF preparation.FIG. 2B shows the scheme of astrocytic reprogramming with compound treatment. MEFM: MEF medium; iAM: induced astrocyte medium; AM: astrocyte medium.FIG. 2C shows immunostaining for GFAP and S100β in cells derived from MEFs treated with DMSO or VC6TO for 25 days. Nuclei were counter-stained with Dapi. Scale bar, 100 μm.FIGS. 2D and 2E show the percentage of GFAP-positive cells and GFAP and S100βdouble positive cells from total cells. n=3,000 to 4,000 cells. -
FIGS. 3A-3H illustrate that a TGFβ inhibitor is critical for astrocytic reprogramming.FIGS. 3A, 3C, 3E and 3G show immunostaining for GFAP in cells derived from MEFs treated with DMSO control or different compound combinations for 25 days. Nuclei were counter-stained with Dapi. Scale bar, 100 μm.FIGS. 3B, 3D, 3F, and 3H show the percentage of GFAP-positive cells in MEFs treated with individual compound combinations described in panels 3A, 3C, 3E, and 3G. n=2,000 to 6,000 cells. -
FIGS. 4A-4D illustrate that the treatment with VCSTO inhibited TGFβ target genes.FIG. 4A shows immunostaining for GFAP in cells reprogrammed from MEFs treated with VCSTO at different concentrations of S (SB-431542). Scale bar, 100 μm.FIG. 4B shows the percentage of GFAP-positive cells in MEFs treated with VCSTO at different concentrations of S. n=2,000 to 6,000 cells counted for each treatment group.FIG. 4C shows that treatment with VCSTO exerted no cellular toxicity. MEFs were treated with DMSO or VCSTO with increasing concentrations of S. Cell toxicity was determined by countinglive cells 1 week or 2 weeks after vehicle or compound treatment. Error bars are sd of the mean. n=4 experimental repeats for each treatment group.FIG. 4D shows relative expression levels of TGFβ downstream target genes in MEFs treated with vehicle only or VCSTO compounds, measured by real time PCR. The expression in MEFs treated with vehicle control was defined as 1. n=3 experimental repeats. -
FIGS. 5A-5C illustrate astrocytic reprogramming by VCSTO in tail tip fibroblasts.FIG. 5A shows immunostaining for GFAP and S100β in cells generated from tail tip fibroblasts (TTFs) treated with VCSTO for 25 days. Nuclei Dapi staining is shown in blue in the merged image. Scale bar, 50 μm.FIGS. 5B and 5C show quantification of the percentage of GFAP-positive cells (5B) and GFAP and S100β-double positive cells (5C) in total Dapi-positive cells. For panels 5B and 5C, error bars are sd of the mean. ***p<0.001. n=967 cells for TTF-DMSO, n=1118 cells for TTF-VCSTO. -
FIGS. 6A-6I illustrate expression of astrocytic markers from VCSTO-induced cells.FIGS. 6A-6C show immunostaining for GFAP and S1008 (6A), GFAP and ALDH1L1 (6B), GFAP and visualizing GFAP-GFP (6C) in VCSTO-induced cells. Nuclei Dapi staining (blue) is included in the merged images. Scale bar, 50 μm. In panel 6C, MEF from GFAP-GFP mice were induced by VCSTO.FIG. 6D shows the expression of astrocyte-related genes in VCSTO-induced astrocytes (iA), relative to MEF, measured by real time PCR. The expression in MEF was defined as 1. n=3 experimental repeats.FIG. 6E shows bisulfite sequencing the Gfap promoter region in MEF, iA and mouse primary astrocytes (pA). Open and closed circles indicate unmethylated and methylated CpGs, respectively.FIG. 6F shows immunostaining for GFAP in cells treated with VCSTO for 10, 15, 20 and 25 days. Scale bar, 100 μm. -
FIG. 6G shows the percentage of GFAP-positive cells in cells treated with VCSTO for different days.FIG. 6H shows real time PCR of astrocyte markers at different days of VCSTO treatment. The expression atday 0 was defined as 1. n=3 experimental repeats.FIG. 6I shows RT-PCR of pluripotency markers, Oct4 and Nanog, and neural progenitor markers, Sox1 and Pax6, during the time course of VCSTO treatment. RNA from mouse embryonic stem cells (ESC) and neural progenitor cells (NPC) was included as positive controls. -
FIGS. 7A-7G illustrate genomic-wide transcriptional profiling of VCSTO-induced astrocytes.FIG. 7A shows heatmap presentation of microarray analysis of MEFs, VCSTO-induced astrocytes (iA) and mouse primary astrocytes (pA). Genes upregulated in iA and pA, compared to MEFs, are shown in red, whereas genes downregulated in iA and pA, compared to MEFs, are shown in blue. InFIG. 7B , gene ontology (GO) terms for genes upregulated in both iA and pA, relative to MEFs, are shown in red, whereas GO terms associated with genes downregulated in iA and pA are shown in blue. The X axis represents enrichment scores, with p value calculated via Fisher's exact test.FIG. 7C shows heatmap presentation of a selected set of fibroblast-related genes (the upper 4 genes) and astrocyte-related genes (the lower 4 genes).FIGS. 7D and 7E show real time PCR validation of the expression of 4 fibroblast-associated genes (7D) and 4 astrocyte-associated genes (7E). The expression in MEFs was defined as 1. n=3 experimental repeats.FIG. 7F shows schematic presentation of different regions of the brain.FIG. 7G shows relative expression of regional subtype markers in iA measured by real time PCR. FB: forebrain; HB: hindbrain; DB: dorsal brain; VB: ventral brain. n=3 experimental repeats. -
FIGS. 8A-8E illustrate gene expression analysis of VCSTO-induced astrocytes.FIG. 8A shows hierarchical clustering of induced astrocytes (iA), primary astrocytes (pA) and MEF based on all the probe sets in microarray data.FIG. 8B shows Pearson's correlation analysis of iA, pA, and MEF.FIGS. 8C and 8D show RT-PCR analysis of 3 fibroblast genes (8C) and 3 astrocyte marker genes (8D) in MEF, iA and pA. The expression in MEF was defined as 1.FIG. 8E shows relative expression of regional subtype markers in iA measured by real time PCR. FB: forebrain; HB: hindbrain; DB: dorsal brain; VB: ventral brain. Error bars are sd of the mean. **p<0.01, ***p<0.001 by Student's t-test. n=3 experimental repeats. -
FIGS. 9A-9I show that compound-induced astrocytes are functional.FIG. 9A shows immunostaining mouse primary cortical neurons for Map2 and Synapsin after co-culturing with MEF, induced astrocytes (iA), and mouse primary astrocytes (pA) for 5 days. Scale bar, 50 μm.FIG. 9B shows quantification of Map2+ neurite length in neurons co-cultured with MEF, iA and pA. n=1,000 cells.FIG. 9C shows increased Map2+ Synapsin+ puncta in neurons co-cultured with iA and pA, relative to co-culture with MEF. Scale bar, 10 μm.FIG. 9D shows quantification of Map2+Synapsin+ puncta per 50 μm neurite length in neurons co-cultured with MEF, iA and pA. n=30 neurites.FIG. 9E shows measurement of glutamate uptake in iA, PA and MEF. n=3 experimental repeats.FIG. 9F shows calcium signal change in response to glutamate stimulation shown by calcium reporter fluorescent dye intensity change (ΔF/F0) over time (second, s) in iA. Scale bar, 100 μm.FIG. 9G shows lack of calcium spikes after glutamate stimulation in MEF.FIG. 9H shows calcium spikes after glutamate stimulation in pA.FIG. 9I shows quantification of ΔF/F0 in MEF, iA and pA in response to glutamate stimulation. n=400 to 600 cells. -
FIG. 10 illustrates Sholl analysis of neurite complexity in co-cultured neurons. Neurons were co-cultured with MEF, induced astrocytes (iA), or mouse primary astrocytes (pA), respectively. Errors bars are sd of the mean. -
FIGS. 11A-11D illustrate VCSTO-induced astrocytes survived and maintained astrocytic marker expression in vivo.FIG. 11A shows timeline of cell transplantation and brain harvest.FIG. 11B shows two examples of GFP-labeled VCSTO-induced astrocytes (iA) in grafted brains that stained positive for both GFP and GFAP. The endogenous astrocytes are shown as GFP-negative but GFAP-positive. Scale bar, 25 μm.FIG. 11C shows higher magnification images of individual GFP and GFAP double positive cells that are indicated by arrows in panel b. Scale bar, 10 μm.FIG. 11D shows that MEF failed to survive in transplanted brains. MEF were labeled by GFP and transplanted into brains of neonatal immunodeficient mice. No GFP signal was detected in various regions of MEF-transplanted brains two weeks after transplantation. Scale bar, 25 μm. -
FIGS. 12A-12E illustrate recapitulating GFAP protein aggregates in VCSTO-induced astrocytes (iA) transfected with an AxD mutant GFAP.FIG. 12A shows transfection of the R239C AxD mutant GFAP-GFP to iA induced GFAP protein aggregates and αβ-crystallin expression. iA transfected with the WT and AxD GFAP-GFP were immunostained for GFAP and αβ-crystallin. The transfected cells are indicated by GFP. Nuclei Dapi staining (blue) is included in the merged images. Scale bar, 10 μm.FIG. 12B shows that ceftriaxone treatment reduced GFAP protein aggregates in iA transfected with the AxD mutant GFAP-GFP. iA transfected with the AxD GFAP-GFP were treated with ceftriaxone (+Cef) or vehicle control (−Cef), and stained for GFAP and S1008. Scale bar, 10 μm.FIG. 12C shows that ceftriaxone treatment reduced GFAP protein aggregates in induced astrocytes (iA) transfected with the AxD mutant GFAP-GFP. The percentage of iA that contained the GFAP-GFP aggregates was reduced upon ceftriaxone treatment. n=400 to 500 cells.FIG. 12D shows that ceftriaxone treatment had no effect on GFAP protein aggregates in MEF. MEF transduced with the AxD GFAP-GFP were treated with ceftriaxone (+Cef) or vehicle control (−Cef). The percentage of MEF that contain the GFAP-GFP aggregates remained the same in the absence or presence of ceftriaxone treatment. n=600 to 900 cells.FIG. 12E shows reduced glutamate uptake in iA tranduced with AxD mutant GFAP, compared to iA transduced with WT GFAP. n=3 experimental repeats. Error bars are sd of the mean, **p<0.01 by Student's t-test. -
FIGS. 13A-13J illustrate reprogramming human fibroblasts into astrocytic cells by VCSTO.FIG. 13A shows immunostaining for S100β in cells derived from human fibroblasts (SCC058, for panels 13A to 13E) treated with DMSO or VCSTO. Nuclei were counter-stained with Dapi. Scale bar, 100 μm for panels 13A and 13B.FIG. 13B shows immunostaining for S100β or GFAP in cells derived from human fibroblasts treated with DMSO or VCSTO, followed by CNTF treatment.FIG. 13C shows the percentage of S100β-positive cells or GFAP-positive cells. n=3,000 to 4,000 cells.FIG. 13D show expression of astrocyte marker genes in VCSTO-induced human astrocytes (iA) as measured by real time PCR. The expression in human fibroblasts (hF) was defined as 1. n=4 experimental repeats.FIG. 13E shows substantially elevated glutamate uptake in iA relative to parental fibroblasts (hF). n=3 experimental repeats.FIG. 13F shows calcium imaging analysis of human induced astrocytes. Human induced astrocytes (iA) exhibited calcium signal change in response to glutamate stimulation, similar to human iPSC-derived astrocytes (hA). Lack of calcium spikes after glutamate stimulation in human fibroblasts (hF) was included as a negative control.FIG. 13G shows immunostaining for S100β and GFAP in cells derived from human adult fibroblasts (AG14048, for panels 13G to 13J) treated with DMSO or VCSTO. Nuclei were counter-stained with Dapi. Scale bar, 100 μm.FIG. 13H shows the percentage of S100β-positive cells or GFAP-positive cells. n=1,000 cells.FIG. 13I shows expression of astrocyte marker genes in iA relative to hF as measured by real time PCR. n=4 experimental repeats.FIG. 13J shows substantially elevated glutamate uptake in human iA relative to hF. n=3 experimental repeats. - The following description of the invention is merely intended to illustrate various embodiments of the invention. As such, the specific modifications discussed are not to be construed as limitations on the scope of the invention. It will be apparent to one skilled in the art that various equivalents, changes, and modifications may be made without departing from the scope of the invention, and it is understood that such equivalent embodiments are to be included herein.
- Expression of lineage-specific factors has been shown to induce cell fate change, including reprogramming somatic cells to induced pluripotent stem cells (iPSCs) (Takahashi and Yamanaka, 2006) and converting one type of somatic cells to another (Davis et al., 1987). The latter is also called direct reprogramming or conversion. Extensive efforts have been devoted into converting somatic cells, like fibroblasts, into different types of neural cells, such as neural stem cells (Kim et al., 2011; Han et al., 2012; Lujan et al., 2012), neurons (Vierbuchen et al., 2010; Caiazzo et al., 2011; Pang et al., 2011; Yoo et al., 2011), and oligodendrocytes (Najm et al., 2013; Yang et al., 2013). Direct reprogramming of somatic cells into astrocytes using defined transcription factors has been reported (Caiazzo et al., 2015). However, the conventional technologies have certain restrictions. For example, the process of inducing human iPSCs from somatic cells such as fibroblasts and then converting human iPSCs to astrocytes is a lengthy process and takes about 90 days or even longer. Direct reprogramming of somatic cells into astrocytes using certain transcription factors involves introducing transgenes and therefore leaves “footprint” of residual transgenes or other contaminants.
- Introducing exogenous factors in reprogramming has raised various concerns, including the risk of insertional mutagenesis and genetic alteration associated with retroviral delivery (Hawley, 2008), low reprogramming efficiency associated with episomal transfection (Okita et al., 2008). Cocktails of small molecules were shown to convert mouse or human fibroblasts into neurons (Hu et al., 2015; Li et al., 2015). However, no chemical reprogramming has been reported to change fibroblasts, or any other mature cell types, to astrocytes yet.
- The technology and methods disclosed herein solves the problems in the art by direct reprogramming or converting somatic cells such as fibroblasts into astrocytes using one or more small molecules without the requirement of producing any intermediate stem cells and without introducing any transgene or contaminant. The process of direct reprogramming disclosed herein takes much shorter time, e.g., less than or about 30 days, than the conventional technology, e.g., 90 days.
- As described in this disclosure, mouse or human fibroblasts were reprogrammed into functional astrocytes, which possess the ability to promote neuronal maturation and synaptic formation, uptake glutamate, and induce calcium signal in response to glutamate stimulation. Although rapid progress has been made in converting somatic cells into other types of neural cells, such as neural stem cells, neurons, and oligodendrocytes, direct reprogramming of somatic cells into astrocytes remains largely behind. Induced neurons can be developed into useful tools for modeling a variety of neurological diseases affecting neurons (Lujan and Wernig, 2012). However, induced neuronal cells would have limitations for modeling disease affecting astrocytes. Although astrocytes could be derived from iPSCs, the differentiation process is lengthy. These limitations could be overcome by inducing astrocytes directly from fibroblasts in a relatively short period of time as described in detail in this disclosure.
- Disclosed herein is an example of pure chemical induction of lineage conversion from a mature somatic cell type to astrocytes. A previous study reported the derivation of iPSCs from mouse somatic cells using 6 small molecules VC6TFZ (Hou et al., 2013). Part of this compound cocktail, VC6 was used to convert somatic cells into neural progenitor cells under hypoxia (Cheng et al., 2014). In recent studies, different combinations of small molecules were used to convert somatic cells into neuronal cells (Hu et al., 2015; Li et al., 2015; Zhang et al., 2015). Disclosed herein is a method to reprogram mammalian fibroblasts into astrocytes using small molecule compounds only, without using any transgenes or viral transduction. Moreover, it was unexpectedly found that the TGFβ inhibitor alone was able to induce GFAP-positive cells from MEFs, providing an example that one single compound is able to induce the conversion of one somatic cell type to another.
- Previous studies described ways to derive astrocytes from somatic cells by going through iPSC or iNSC/iNPC intermediates (Han et al., 2012; Lujan et al., 2012; Ring et al., 2012; Thier et al., 2012; Cassady et al., 2014). In these studies, astrocytes were derived from MEFs at an efficiency of 0.004% to 2% in up to 70 days. Disclosed herein is a direct reprogramming method that does not go through iPSC or iNSC/iNPC intermediate state. Astrocytes can be converted from MEFs at an efficiency of about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, or about 100%, in a shorter period of time, such as 20 to 25 days, by the method disclosed herein. Therefore, the direct chemical reprogramming method described in this disclosure provides a more rapid and efficient way to derive astrocytes from fibroblasts.
- As disclosed herein, the chemically induced astrocytes can be used to model diseases with astrocyte dysfunction. The working examples demonstrate that when an AxD mutant GFAP was transfected into induced astrocytes, the phenotype of GFAP protein aggregation observed in AxD patient astrocytes was recapitulated. Moreover, these protein aggregates were responsive to ceftriaxone treatment. Therefore, the chemically induced astrocytes disclosed herein can be used as a tool to study neurodevelopment in glial context, and to model a variety of neurological diseases with astrocyte dysfunction. Additionally, induced astrocytes containing disease-causing mutations can be produced by the methods disclosed herein. The induced astrocytes, as well as induced astrocytes containing mutations can be used for detecting, preventing or treating astrocyte-associated diseases.
- In one aspect, disclosed herein is a method of reprogramming or converting somatic tissue or cells into astrocytes or astroglial progenitor cells using one or more small molecules only, without introducing any transgenes. In some embodiments, the somatic tissue or cells to be converted into astrocytes or astroglial progenitor cells are autologous tissue or cells. In some embodiments, the somatic tissue or cells that can be converted to astrocytes or astroglial progenitor cells include fibroblasts, urinary cells, blood cells, adipocytes, keratinocytes, and dental pulp cells.
- The method includes contacting the somatic tissue or cells with one or more small molecules, wherein the one or more small molecules include at least one TGF-β inhibitor. In some embodiments, the TGF-β inhibitor is an inhibitor of TGF-βR1 (ALK5). The somatic tissue or cells are cultured in the presence of the one or more small molecules under a suitable condition for a period of time sufficient for the somatic tissue or cells to be converted into astrocytes or astroglial progenitor cells.
- In some embodiments, a single small molecule is sufficient to induce the conversion to astrocytes or astroglial progenitor cells, and the small molecule is a TGF-βinhibitor. In other embodiments, two or more small molecules are used, and at least one small molecule is a TGF-β inhibitor.
- Small molecule TGF-β inhibitors are known in the art (Calone 2012) and many are commercially available. Some examples of TGF-β inhibitors include but are not limited to 616452, A-83-01, SB-431542, SD-208, LY 2109761, GW 788388, LDN-212854, A 77-01, LY2157299, K02288, ML347, and SB-505124 hydrochloride, as shown in Table 1 below.
-
TABLE 1 TGF-β Inhibitors Small Molecule Chemical Name Chemical Structure 616452 ( Alk 5 Inhibitor II or RepSox)2-[5-(6-methylpyridin-2-yl)- 1H-pyrazol-4-yl]-1,5- naphthyridine A-83-01 3-(6-methylpyridin-2-yl)-N- phenyl-4-quinolin-4- ylpyrazole-1-carbothioamide SB-431542 4-[4-(1,3-benzodioxol-5-yl)-5- pyridin-2-yl-1H-imidazol-2- yl]benzamide SD-208 2-(5-chloro-2-fluorophenyl)-N- pyridin-4-ylpteridin-4-amine LY 2109761 4-[2-[4-(2-pyridin-2-yl-5,6- dihydro-4H-pyrrolo[1,2- b]pyrazol-3-yl)quinolin-7- yl]oxyethyl]morpholine GW 788388 N-(oxan-4-yl)-4-[4-(5-pyridin- 2-yl-1H-pyrazol-4-yl)pyridin-2- yl]benzamide LDN-212854 5-[6-[4-(1- Piperazinyl)phenyl]pyrazolo[1,5- a]pyrimidin-3-yl]quinoline A 77-01 4-[5-(6-methylpyridin-2-yl)- 1H-pyrazol-4-yl]quinoline LY2157299 4-[2-(6-methylpyridin-2-yl)- 5,6-dihydro-4H-pyrrolo[1,2- b]pyrazol-3-yl]quinoline-6- carboxamide K02288 3-[6-amino-5-(3,4,5- trimethoxyphenyl)pyridin-3- yl]phenol ML347 5-[6-(4- Methoxyphenyl)pyrazolo[1,5- a]pyrimidin-3-yl]quinoline SB-505124 hydrochloride 2-[4-(1,3-benzodioxol-5-yl)-2- tert-butyl-1H-imidazol-5-yl]-6- methylpyridine - In some embodiments, two or more small molecules are used. In combination with a TGF-β inhibitor, at least one of a histone deacetylase (HDAC) inhibitor, a GSK3β inhibitor, a lysine specific histone demethylase 1 (LSD1) inhibitor, and an Oct4-activating compound can be used. Some examples of each category are provided in the tables below.
-
TABLE 3 GSK3β Inhibitors Small Molecule Chemical Structure GSK-3 Inhibitor IX Kenpaullone Lithium Chloride Li+ Cl− GSK-3β Inhibitor XII GSK-3 Inhibitor XVI 10Z-Hymenialdisine CHIR-98014 GSK-3β Inhibitor VI GSK-3β Inhibitor I GSK-3β Inhibitor VII 3F8 GSK-3 Inhibitor II GSK-3β Inhibitor VIII GSK-3β Inhibitor XI - OAC compounds have the following structure with each substituent group listed in Table 5:
-
TABLE 5 OAC Compounds Oct4- Oct4-luc Enhance luc fold reprogramming Compound X Y Z R1 R2 R3 R4 R5 Activity Induction efficiency C1 N C C H H H H H Active 4.72 YES C2 CH C C H H H H H Active 4.15 YES C3 CH C C H H F H H Active 3.84 YES C4 CH C C H H MeO H H Active 5.46 ND C5 CH C C H ═N—O—N═ H H Active 2.87 ND C6 CH N C H H MeO H — Active 3.18 ND C7 CH N C H H F H — Active 2.2 ND C8 CH N C H H H H — Active 1.89 ND C9 CH N C H H EtO H — Active 7.22 ND C10 CH N C H H Et H — Active 4.51 ND C11 CH N C H H iso-Pr H — Active 3.78 ND C12 CH N C Cl H Cl H — Active 3.6 ND C13 CH N C H Me Me H — Active 2.78 ND C14 CH N C H EtO H H — Active 2.67 ND C15 CH N C H MeO H H — Active 1.93 ND C16 CH C C H H F H Inactive 1 ND C17 CH C C H H Me CN H Inactive 1.1 ND C18 CH N C H F H H — Inactive 1.27 ND C19 CH N C H Cl H H — Inactive 1.65 ND C20 CH N C H Br H H — Inactive 1.48 ND C21 CH N C H CF3 H H — Inactive 1.48 ND C22 CH N C F H H H — Inactive 1.5 ND C23 CH N C Cl H H H — Inactive 1.72 ND C24 CH N C Br H H H — Inactive 1.46 ND C25 CH N C MeO H H H — Inactive 1.5 ND C26 CH N C EtO H H H — Inactive 1.22 ND C27 CH N C MeO MeO H H — Inactive 1.37 ND C28 CH N C MeO H MeO H — Inactive 1.42 ND C29 CH N C H MeO MeO H — Inactive 1.13 ND C30 CH N C H EtO EtO H — Inactive 1 ND C31 CH N N H Cl H — — Inactive 1 ND C32 CH C N H H NO2 — Me Inactive 1.3 ND - Table 5 shows the Oct4-activating activity of compound Cl and its structural analogs. Compounds that induce Oct4-luc 1.8-fold or more were classified as being “active”, and molecules that induce Oct4-luc less than 1.8-fold were indicated as being “inactive”. ND: not determined.
- These inhibitors and compounds are known in the art. Therefore, it is within the purview of one skilled in the art to select a suitable compound from each category and/or to select a suitable combination of different categories. For example, a TGF-β inhibitor is used in combination with a histone deacetylase inhibitor, or in combination with a histone deacetylase inhibitor and a GSK3β inhibitor. Other examples include the combination of a TGF-β inhibitor with a histone deacetylase inhibitor and a GSK3β inhibitor, a TGF-β inhibitor with a histone deacetylase inhibitor and an Oct4-activating compound, or a TGF-β inhibitor with a LSD1 inhibitor and an Oct4-activating compound. The combinations of a TGF-β inhibitor with different categories of at least one of a histone deacetylase inhibitor, a GSK3β inhibitor, a lysine specific histone demethylase 1 (LSD1) inhibitor, and an Oct4-activating compound are for illustration purposes only and are not intended to limit the scope of this invention.
- In some embodiments, one or more small molecules include a combination of a histone deacetylase inhibitor VPA (V), a GSK3β inhibitor CHIR99021 (C), a TGF-β inhibitor 616452 (6), A-83-01 (A) or SB-431542 (S), a lysine specific histone demethylase LSD1 inhibitor tranylcypromine (T), and an Oct4-activating compound OAC1 (0). In some embodiments, the combination of the small molecules is “VC6TO,” “VCATO,” or “VCSTO,” which includes the compounds disclosed herein. In a preferred embodiment, the combination comprises at least one small molecule that is a TGF-β inhibitor.
- In some embodiments, the concentration of a TGF-β inhibitor, either used alone or in combination with one or more other small molecules, is within a range between 1 μM and 100 μM, between 2 μM and 50 μM, between 3 μM and 30 μM, between 5 μM and 10 μM. In some embodiment, the concentration of a TGF-β inhibitor is about 1 μM, about 2 μM, about 3 μM, about 4 μM, about 5 μM, about 6 μM, about 7 μM, about 8 μM, about 9 μM, about 10 μM, about 11 μM, about 12 μM, about 13 μM, about 14 μM, about 15 μM, about 20 μM, about 25 μM, about 30 μM, about 35 μM, about 40 μM, about 45 μM, or about 50 μM, without causing significant cytotoxicity.
- Upon culturing the somatic tissue or cells in the presence of one or more small molecules for a period of between 7 days and 90 days, between 10 days and 60 days, between 15 days and 45 days or between 20 days and 30 days, the somatic tissue or cells are reprogrammed or converted into functional astrocytes or astroglial progenitor cells. It is within the purview of one skilled in the art to adjust the culturing period to optimize the percentage of conversion, for example, by choosing different combinations of the small molecules. The induced astrocytes or astroglial progenitor cells contain either or both of anterior and posterior subtypes. The induced astrocytes or astroglial progenitor cells can also contain either or both of dorsal and ventral subtypes.
- As discussed in the examples below, the one or more small molecules disclosed herein can reprogram or convert somatic tissue or cells to astrocytes or astroglial progenitor cells. The mouse or human induced astrocytes resemble primary astrocytes in astrocytic gene expression and epigenetic status, and exhibit functional properties in promoting neuronal maturation, glutamate uptake and calcium signaling. Moreover, these cells can recapitulate Alexander disease phenotype of protein aggregation when expressing Gfap with a disease-causing mutation. The same compounds can also reprogram human fibroblasts into astroglial progenitor cells that can be further matured into functional astrocytes. Therefore, these induced astrocytes can be used in methods for preventing or treating neurodevelopmental disorders or neurological diseases that are associated with dysfunction of astrocytes. These induced astrocytes can also be used to screen and test candidate drugs for these diseases.
- In some embodiments, this disclosure relates to a method of preventing or treating a neurodegenerative disease or a neurological disorder associated with astrocyte dysfunction in a subject. The method entails reprogramming or converting somatic tissue or cells into astrocytes or astroglial progenitor cells using one or more small molecule compounds as disclosed herein, and transplanting the astrocytes or astroglial progenitor cells into the brain of the subject suffering from the neurodegenerative disease or neurological disorder. In some embodiments, the somatic tissue or cells are autologous tissue or cells isolated from the subject to be treated. In some embodiments, the somatic tissue or cells that can be converted to astrocytes or astroglial progenitor cells include fibroblasts, urinary cells, and blood cells. The neurodegenerative diseases or neurological disorders associated with astrocyte dysfunction include, for example, Alzheimer's disease, Alexander disease, Parkinson's disease, Huntington disease, amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), epilepsy, stroke and cerebral ischemia.
- The terms “treat,” “treating,” or “treatment” as used herein with regards to a condition refers to preventing the condition, slowing the onset or rate of development of the condition, reducing the risk of developing the condition, preventing or delaying the development of symptoms associated with the condition, reducing or ending symptoms associated with the condition, generating a complete or partial regression of the condition, or some combination thereof. In some embodiments, treating a condition means that the condition is cured without recurrence.
- The working examples below further illustrate various embodiments of this disclosure. By no means the working examples limit the scope of this invention.
- Cell culture. MEFs and TTFs were derived from E13.5 embryos of Oct4-GFP transgenic (OG2) mice (Szabo et al., 2002), wild type or GFAP-GFP transgenic mice (Jackson Laboratory) (Zhuo et al., 1997). These cells were cultured in MEF medium containing DMEM, 10% FBS, 0.1 mM nonessential amino acids, and 2 mM L-glutamine. Mouse primary astrocytes were isolated from P1-2 pups following published protocol (Schildge et al., 2013) and cultured in DMEM containing 10% FBS.
- Direct reprogramming mouse fibroblasts into astrocytes. MEFs were plated on 6-well or 12-well plates at a cell density of 3×103 cells/cm2. Cells were cultured in MEF medium for 24 hr, then changed to mouse induced astrocyte medium (iAM) containing knock-out DMEM with 10% knock-out serum replacer, 10% FBS, 2 mM L-glutamine, 0.1 mM NEAA, 0.1 mM β-mercaptoethanol, and 100 ng/ml FGF. Cells were treated with compounds, including 500 nM valproaic acid (VPA) (Stemgent), 3 μM CHIR99021(D&C chemicals), 10 μM SB-431542 (D&C chemicals), 10 μM Tranylcypromine (Stemgent), and 1 μM OAC1(Li et al., 2012) for 10 days, re-plated onto Matrigel-coated plates (BD Biosciences) and continued with compound treatment for another 15 days. Cells were then switched to mouse astrocyte medium (AM) containing DMEM with 10% heat-inactivated FBS.
- Immunocytochemistry. Cells were fixed in 4% paraformaldehyde (PFA) for 10 min, followed by washes in PBS at room temperature (RT). Cells were then blocked with 3% donkey serum in PBS containing 0.01% Triton-
X 100 for 1 h at RT, and incubated with primary antibodies overnight at 4° C., then washed with PBS and incubated with secondary antibodies for 1 h at RT. Primary antibodies for GFAP (1:2000, DAKO, Z0334), S100β (1:200, NOVUS, NB110-57478), ALDH1L1 (1:200, NeuroMab, 75-140), Synapsin (1:1000, SYSY, 106103), αβ-crystallin (1:200, Enzo, ADI-SPA-223), MAP2 (1:500, GeneTex, GTX11268), Tuj1 (1:6,000, Covance, PRB-435P), NeuN (1:400, Millipore, MAB377), Pax6 (1:500, Covance, PRB-278P), Sox1 (1:500, Millipore, AB15766), Oligo2 (1:200, GeneTex, GTX62440), NG2 (1:500, Millipore, MAB5384), NKX2.2 (1:50, DSHB, 745A5) were used. Nuclei were stained with DAPI (1:6,000, Sigma, D9564). - Cell sorting and microarray gene expression analysis. GFAP-GFP positive iAs were sorted using the FACSAria III cell sorter (BD Bioscience). Gene expression profiling was performed using Mouse Gene 2.0 ST array (Affymetrix). Microarray data analysis was performed using Partek® Genomics Suite™ (Partek, Inc.). Expression values were Robust Multi-array Average (RMA) normalized (Irizarry et al., 2003). Fold-change values represent the linear ratio between signal intensities when the ratio value is greater than 1 and -1/ratio when the ratio is less than 1. Genes were defined as differentially expressed if they showed a fold-change value >1.5. Heatmaps to visualize differentially expressed genes were produced in Partek using Euclidian distance for hierarchical clustering of standardized expression values. Gene Ontology enrichment was performed for functional enrichment of commonly affected genes, with p-values calculated via Fisher's exact test. Microarray data have been deposited to NCBI's GEO under accession number GSE81927.
- Real time PCR. Total RNA was extracted using Trizol reagent (Qiagen), cDNAs were prepared using Tetro cDNA synthesis kit (Bioline). Real time PCR was performed using DyNAmo Flash SYBR Green qPCR mix on a StepOnePlus system (Applied Biosciences) and normalized to β-Actin. Primers used are listed in Table 6 below.
-
Gene Forward sequence Reverse sequence Gfap GAAGTTCGAGAACTCCGGGAG TTAGACCGATACCACTCCTCTG mS100B CCCTCATTGATGTCTTCCACCA CTTCGTCCAGCGTCTCCATCAC Aldh1L1 GGAAGACAGCAGCCTGCCTG CTTCACATTACTCAGGGCAC NFIA ACAGGTGGGGTTCCTCAATC GAGGCTTGGTGTCTGGCATG Ctnnall GGAGAAGGTCACGGAGATCG TGAAGTCCTCCACATGCTCC Ndp TGGACTCTCAACGCTGCATG GGACAGTGCTGAAGGACACC Lix1 GGAGTTCATCATGGAGAGTG CATTCCAGTGCAGTAGTTGG Sox6 CTTGCCGATGTGGTGGATAC CTCTGCAAGGCTCTTGGTG Tlr3 TCACTTGCTCATTCTCCCTT GACCTCTCCATTCCTGGC Let7b TCGACTCGAGCCCTCTCACTGAACC GCGAATTCTTAATAAAAACCACCC TCTGTCTCC AATCTGTGGCTCCA Col12a1 AGGAGTTGATGAGCAGCTTG GGTCACGAACATTGAGCGTG Col6a3 TCTTGAACGTGTGGCTAACC TCTCCAGAGCACTTGCATGG Col3a1 GCCCACAGCCTTCTACAC CCAGGGTCACCATTTCTC Col1a1 GCAACAGTCGCTTCACCTACA CAATCTTCCAAGGGAGCCACAT P21 AATCCTGGTGATGTCCGACC CAAAGTTCCACCGTTCTCGC ATF4 GAGCTTCCTGAACAGCGAAGTG TGGCCACCTCCAGATAGTCATC P27 GCCTGACTCGTCAGACAATC CGTCTGCTCCACAGTGCCAG DCN TGAGCTTCAACAGCATCACC AAGTCATTTTGCCCAACTGC Gadd45b CCTGGCCATAGACGAAGAAG AGCCTCTGCATGCCTGATAC IFRD1 ACAGGCAGCTCTTGAAGGTC AGACACCGCTCAATGCTATC TGFB111 GCCTCTGTGGCTCCTGCAATAAAC CTTCTCGAAGAAGCTGCTGCCTC TGFB1 CCAAGTCACCCTACCAGCTG TCCTCTGGTACCACTGCTTG TSC22D1 GCTGCTGCTGCTGTCTGAAC ACATCCCTGCTCACTCTCTG FOXG1 TGGCAACACTGCCCATTCA GCATTTGCGCAACACAGGTTA Hoxb4 TTCACGTGAGCACGGTAAAC CACTTCATGCGCCGATTCTG NKX2.1 AAAACTGCGGGGATCTGAG TGCTTTGGACTCATCGACAT Pax3 ACTACCCAGACATTTACACCAGG AATGAGATGGTTGAAAGCCATCAG Sox1 CCAAGAGACTGCGCGCGCTG TGAGCAGCGTCTTGGTCTTG Pax6 ACCAAAGGGTCATCGCGCCC TGGCAGTCCTTGCGATCGGC Oct4 TAGGTGAGCCGTCTTCCAC GCTTAGCCAGGTTCGAGGAT Nanog CAGGAGTTTGAGGGTAGCTC CGGTTCATCATGGTACAGTC AQP4 TTCTCTTCGGTGCTAGGAAAC AGGAAGCTTATGTCTCTGGTG Glast1 CTAGTTGTCTTCTCCATGTG AGGAGAGGCAGGACGATGAC Glt1 GCGCATGTGCGACAAGCTGG GCGATGCCAAGCGAAGCAGC 36B4 TGGTGCTGATGGGCAAGAA ATTCCCCCGGATATGAGGC Actin CCGAGCGTGGCTACAGCTTC ACCTGGCCGTCAGGCAGCTC mGfap TTGTTGGTATGGAGTATAGGTTGTT CCTACCTTCCTCTACCCATACTTAA GTTAT ACT - Astrocyte-neuron co-cultures. Mouse cortical neurons were isolated from E13.5 mouse embryo and cultured in neuronal culture media (neurobasal, 1X B27, 2 mM L-glutamine) alone or directly on a layer of induced astrocytes (iA), mouse primary astrocytes (pA) or MEF for 5 days. Mouse neurons, iA, pA or MEFs were plated at the same density of 10,000 cells/cm2. The co-cultured cells were stained for MAP2 and Synapsin. The Synapsin+puncta along the MAP2+neurites were expressed as the number of puncta per 50 μm neurite length.
- Transplantation. Induced astrocytes labeled by GFP-expressing lentivirus were dissociated using trypsin-EDTA and resuspended in medium at 100,000 cells/μl density and kept on ice. Two μl cell suspensions were injected 1 mm from the midline between the Bregma and Lambda and 1 mm deep into the anterior lateral ventricles of immunodeficient neonatal NSG mice. After 6 weeks, mice were euthanized and perfused with 4% PFA for 5 min. Brain tissues were harvested for immunostaining. All animal work was performed under the IACUC protocol approved by the City of Hope IACUC Committee.
- Ca2+imaging. Cells were seeded in 12-well plates at a density of 1×105 cells per well and stimulated with 10 μM glutamic acid. Fluo-4 Calcium Imaging Kit (Invitrogen F10489) was used to monitor calcium waves following manufacturer's instructions. Calcium waves were captured using a Zeiss Observer Microscope. Wave intensity was analyzed using Image Pro Premier and the intensity was measured as ΔF/F0=(F-F0)/F0.
- Bisulfite sequencing. Genomic DNAs were isolated from MEF, FACS-sorted induced astrocytes and mouse primary astrocytes using a Genomic DNA Purification Kit (Qiagen). Bisulfite conversion of genomic DNAs was carried out using the EZ DNA Methylation-Gold Kit (Zymo Research). The bisulfite-modified DNA was then used as a template for PCR to amplify the promoter region of Gfap. The amplified products were cloned into the pCR2.1-TOPO cloning vector (Invitrogen), and 10 randomly selected clones were sequenced using T7 or M13R primers.
- Glutamate uptake assay. The glutamate uptake was measured using the Glutamate Assay Kit (BioVision). Induced astrocytes were plated at a concentration of 2×104 cells per well in a 24-well plate. 100 μM L-glutamate was added to each well. After incubation for 6 h, the glutamate concentration in the media was measured and presented as nmol of glutamate per mg of total proteins.
- Transfection into induced astrocytes. Induced astrocytes (iA) were seeded at 1×105 cells per well in 12-well plates and incubated overnight. Then 2 μg plasmid of human wild type (WT) GFAP-GFP or AxD mutant GFAP-GFP with the R239C mutation (Bachetti et al., 2008) was transfected into iA using Lipofectamine® 2000 (Invitrogen). Forty eight hr after transfection, cells were assayed by immunostaining. For drug treatment, 24 hr after transfection, cells were treated with vehicle control or 100 μM ceftriaxone for 48 hr, followed by immunostaining.
- Inducing human fibroblasts for astrocytic conversion. Human fibroblasts were purchased from Millipore (SCC058) or Coriell (AG14048) and tested for lack of mycoplasm contamination. Human fibroblasts were seeded onto 6-well plates at the density of 104 cells/cm2 and cultured in either FibroGRO complete medium (for SCC058) or Eagle's MEM with 15% non-inactivated fetal bovine serum (for AG14048) for 24 hr, then switched to induced astrocyte medium containing DMEM/F12 with 2 mM L-glutamine, 0.1 mM NEAA, 1xN2, 1xB27 and 100 ng/ml FGF. For SCC058, cells were treated with VCSTO compounds, including 500 nM VPA (Stemgent), 3 μM CHIR99021 (D&C chemicals), 10 μM SB-431542 (D&C chemicals), 10 μM Tranylcypromine (Stemgent), and 1 μM OAC1 (Li et al., 2012) for 20 days, re-plated onto Matrigel-coated plates and continued with compound treatment for another 20 days. Cells were then treated with 10 ng/ml CNTF for another 6 days. For AG14048, cells were treated with VCSTO compounds at the same concentration as described above for 30 days, then treated with VCSTO together with 10 ng/ml CNTF for another 10 days.
- FSP1 FACS analysis. MEFs were stained by FSP1 antibody (Millipore, ABF32). FACS analysis was performed on Flow Cytometry Analyzers BD Fortessa (BD Bioscience).
- Statistical analysis. Independent-samples t-test was used to compare means of two independent samples. A value of p<0.05 was considered statistically significant.
- Example 2 A compound cocktail induced the conversion from MEFs to astrocyte-like cells
- A compound combination including the histone deacetylase inhibitor VPA (V), the GSK3β inhibitor CHIR99021 (C), the TGFβ inhibitor 616452 (6), the lysine specific histone demethylase LSD1 inhibitor Tranylcypromine (T), the cyclic AMP inducer forskolin (F), and a histone methylation inhibitor DZNep (Z) was used to reprogram mouse embryonic fibroblasts (MEFs) into iPSCs (Hou et al., 2013). In this chemical cocktail, compounds F and Z were used together to induce the expression of Oct4, a factor critical for reprogramming. It was also reported that a small molecule OAC1 was used as an Oct4-activating compound (Li et al., 2012). In this example, the combination of VC6T with the OAC1 compound (together termed VC6TO) was tested to reprogram MEFs into iPSCs. MEFs were derived from mice harboring an Oct4 promoter-driven GFP (OG2) reporter. However, treatment with VC6TO for up to 25 days failed to induce any Oct4-GFP-positive iPSC colonies from the OG2 MEFs. Instead, cells with astrocyte-like morphology were observed (
FIG. 1A ). - Subsequently, the VC6TO cocktail was tested to see if it could reprogram MEFs into astrocytes. Any neural tissues was excluded from the MEF preparation (
FIG. 2A ) as described (Vierbuchen et al., 2010). Immunostaining MEFs with various neural lineage markers revealed no contamination of neural progenitor cells, neurons, astrocyes, and oligodendrocyte progenitor cells (FIG. 1B ), instead 99.6% cells expressed the fibroblast marker FSP1 (FIG. 1C ). These MEFs were treated with VC6TO and cultured in induced astrocyte medium (FIG. 2B ). Twenty-five days after compound treatment, the resultant cells were immunostained for astrocyte markers, glial fibrillary acidic protein (GFAP) and S100β. 12% GFAP-positive cells with typical astrocyte morphology were detected (FIG. 2C, 2D ). The percentage of GFAP+510013+ cells was similar to that of GFAP+ cells (FIG. 2E ). Together, these results indicate that the VC6TO compounds can reprogram MEFs into GFAP-positive and S100β-positive astrocyte-like cells. - Example 3 A TGFβ inhibitor was critical for astrocytic conversion
- Compounds critical for astrocytic conversion were identified. The combination of VC6, V6, or 6 alone, was able to induce GFAP-positive cells from MEFs, although the efficiency of conversion decreased when the number of compounds was reduced. In contrast, subtraction of
compound 6 from VC6TO led to failure of astrocytic conversion, as revealed by the lack of GFAP-positive cells (FIG. 3A, 3B ). These results suggest thatcompound 6 is necessary and sufficient to induce the conversion of MEFs into astrocyte-like cells. - Since
compound 6 is a transforming growth factor β(TGFβ)receptor 1 kinase inhibitor (Gellibert et al., 2004), other inhibitors ofTGFβ receptor 1 were tested for inducing astrocytic reprogramming together with VCTO. Compound A-83-01 (A) or SB-431542 (S), two well-characterized inhibitors of TGFβ receptor 1 (Inman et al., 2002; Tojo et al., 2005) was tested. Treating MEFs with either the combination of VCTO with A (VCATO) or VCTO with S (VCSTO) induced a substantial increase in GFAP-positive cells with astrocyte morphology (FIG. 3C, 3D ). In contrast, VCTO did not induce any GFAP-positive cells (FIG. 3C, 3D ). VCATO and VCSTO induced more GFAP-positive cells than the initial VC6TO combination (FIG. 3B-3D ), with the highest conversion efficiency observed with VCSTO, which induced 38% GFAP-positive cells atday 25 after compound treatment. The rest of the study was focused on VCSTO-induced reprogramming. - Individual compounds were substracted from VCSTO to determine the effect of individual compounds on astrocytic conversion. Similar to removal of 6, subtraction of S from VCSTO led to almost complete loss of GFAP-positive cells (
FIG. 3E, 3F ). Subtraction of T or C decreased reprogramming efficiency dramatically, whereas removal of V or O reduced the efficiency mildly (FIG. 3E, 3F ). On the other hand, compound S by itself was sufficient to induce GFAP-positive cells from MEFs (FIG. 3G, 3H ). Combination with C and T led to a more robust induction of GFAP-positive cells (FIG. 3G, 3H ). These results indicate that compound S is critical for astrocytic reprogramming, while compounds C and T promote reprogramming efficiency. - Since S was identified as a critical compound for astrocytic reprogramming, the dose response of compound S was determined. MEFs were treated with VCSTO at different concentrations of S from 0 to 10 μM, and observed increased GFAP-positive cells with elevated concentrations of S (
FIG. 4A, 4B ). No toxicity was observed in cells treated with VCSTO at the concentration of S at 10 μM or even higher (20 or 30 μM) (FIG. 4C ). - Since S is an inhibitor of TGFβ receptor 1 (Inman et al., 2002), whether the TGFβ signaling is suppressed by VCSTO treatment was tested. After 24 hr VCSTO treatment of MEFs, dramatic inhibition of gene expression was observed for a set of TGFβ downstream effectors (
FIG. 4D ), including Atf4, Col1a1, decorin (Dcn), Gadd45b, Ifrd1, p21, p27, Tgfb1i1, Tgfbi, and Tsc22d1, consistent with the role of S in inhibiting TGFβ signaling. These results indicate that a TGFβ inhibitor is critical for converting fibroblasts into astrocyte-like cells. - To determine if astrocyte-like cells could also be converted from other cell types, mouse tail-tip fibroblasts (TTFs) were treated with VCSTO compounds. Twenty-five days after VCSTO treatment, GFAP-positive and S100β-positive cells with astrocyte morphology were detected (
FIG. 5A ). The percentage of GFAP+S100β+ cells was similar to that of GFAP+ cells (FIG. 5A-5C ). - Example 4 VCSTO-induced cells express astrocytic genes and exhibit epigenetic reprogramming
- To verify that the VCSTO-reprogrammed cells were indeed astrocytes, astrocytic marker expression in these cells was first determined. Double staining for GFAP and S100β revealed that the VCSTO-induced cells expressed both GFAP and S100β(
FIG. 6A ). In addition to GFAP and S100β, ALDH1L1 has been identified to be a reliable marker for astrocytes (Barres, 2008). Double staining the VCSTO-reprogrammed cells with GFAP and ALDH1L1 revealed that the compound-induced cells were positive for both of these astrocytic markers (FIG. 6B ). These results further confirmed the astrocyte identity of the VCSTO-induced cells. - Because astrocytes could be visualized by GFP fluorescence in the GFAP-GFP reporter mice (Zhuo et al., 1997), MEFs from these mice were derived and treated with VCSTO to monitor astrocytic conversion. GFAP-GFP-positive cells emerged around
day 10 today 15 after VCSTO treatment. The induced cells were visualized for GFAP-GFP fluorescence and immunostained for GFAP atday 25 after VCSTO treatment. Nearly all GFAP-GFP positive cells were also positive for GFAP immunostaining (FIG. 6C ). - Astrocytes express high levels of glutamate transporters, predominantly GLT-1 and GLAST (Chaudhry et al., 1995). Aquaporin 4 (AQP4), a member of the aquaporin family of membrane proteins, is also enriched in astrocytes (Simard and Nedergaard, 2004). Real time PCR revealed that the VCSTO-reprogrammed cells expressed high levels of Glt-1, Glast, and Aqp4, in addition to the astrocytic markers Gfap, S100β, and Aldh1l1 (
FIG. 6D ), further strengthening the conclusion that the VCSTO-reprogrammed cells are astrocytes. - An important aspect of reprogramming is epigenetic reprogramming. Demethylation of the Gfap promoter has been shown to be associated with astrocyte differentiation (Hatada et al., 2008). The Gfap promoter was tested to see if it is demethylated during astrocytic conversion from MEFs. VCSTO-induced cells were sorted for GFAP-positive cells after GFAP staining. The resultant cells were subjected to DNA methylation analysis. Bisulfite sequencing revealed that the Gfap promoter of VCSTO-induced cells was largely demethylated, similar to that in primary astrocytes (
FIG. 6E ), whereas the Gfap promoter in parental MEFs was highly methylated (FIG. 6E ). This result indicates that epigenetic reprogramming occurred during VCSTO-induced astrocytic conversion. - To determine the dynamic expression pattern of astrocytic genes during the conversion, MEFs were treated with VCSTO for various time periods and immunostaining and RT-PCR were performed at
days day 10 after compound treatment, although the efficiency was low (FIG. 6F, 6G ). Byday 15, more than 15% GFAP-positive cells were detected. The rate of conversion further increased with time. Byday 25, GFAP-positive cells reached more than 30% (FIG. 6F, 6G ). In parallel RT-PCR analysis, increased expression of the astrocytic markers Gfap, S100β, and Aldh1l1 was observed along the time course, with the highest induction at day 25 (FIG. 6H ). In contrast, the induction of the pluripotency genes Oct4 and Nanog, and the neural progenitor genes Sox1 and Pax6, was not observed during the same time course (FIG. 6I ), suggesting that these compounds induce astrocytic conversion without inducing iPSC or neural progenitor cell intermediates. - Example 5 Genome-wide remodeling and regional specification in VCSTO-induced astrocytes
- Genome-wide profiling was performed to compare gene expression pattern of VCSTO-induced astrocytes with that of primary astrocytes and MEFs. MEFs were derived from GFAP-GFP reporter mice and treated with VCSTO for 25 days. The reprogrammed cells were sorted for GFAP-GFP-positive cells and subjected to DNA microarray analysis, along with primary astrocytes and MEFs. A heatmap depicting all probe sets that were differentially expressed by at least 1.5-fold showed that the transcriptional program characteristic of MEFs was globally reprogrammed toward that of astrocytic lineage (
FIG. 7A ). Hierarchical clustering revealed that the overall gene expression pattern in induced astrocytes is more similar to that in primary astrocytes than to parent MEFs (FIG. 8A, 8B ). Among the genes up-regulated (≥2-fold) in primary astrocytes compared to MEFs, 53.9% were also up-regulated in iA; among the genes down-regulated in primary astrocytes relative to MEFs, 68.3% were also down-regulated in iA. Genes up-regulated in both induced astrocytes and primary astrocytes, compared to MEFs, were significantly enriched for gene ontology (GO) terms associated with membrane and synapse (FIG. 7B ), consistent with the critical role of astrocytes in synaptogenesis (Hama et al., 2004; Eroglu and Barres, 2010). In contrast, genes down-regulated in both induced astrocytes and primary astrocytes, compared to MEFs, were significantly enriched for GO terms linked to cell cycle and cell division (FIG. 7B ). - Validation of differentially expressed genes revealed that the known fibroblast-related genes were down-regulated in both VCSTO-induced astrocytes and primary astrocytes, compared to MEFs (
FIG. 7C, 7D ,FIG. 8C ). In contrast, genes that are known to be expressed in astrocytes or involved in astrocyte differentiation and functions were strongly up-regulated in both induced and primary astrocytes, compared to MEFs (FIG. 7C, 7E ,FIG. 8D ). These results indicate that induced astrocytes resemble primary astrocytes in genome-wide gene expression profile. - To determine the regional subtypes of VCSTO-induced astrocytes, real time PCR was performed to measure the expression levels of markers for forebrain (Foxg1, Otx1, Otx2), hindbrain (Hoxb4, Egr2, and Grx2), dorsal (Pax3, Trhr) and ventral (Nkx2.1, Lix1) brains (
FIG. 7F &FIG. 8E ). Induced astrocytes expressed both the forebrain markers Foxg1, Otx1 and Otx2, and the hindbrain markers Hoxb4, Egr2 and Grx2, although the expression of the hindbrain markers is more robust (FIG. 7G &FIG. 8E ), suggesting that induced astrocytes contain both anterior and posterior astrocyte subtypes, perhaps with a more abundant subpopulation of posterior astrocytes. As for the dorsal-ventral regionality, VCSTO-induced astrocytes are predominantly dorsal, exhibiting robust Pax3 and Trhr expression, but barely detectable Nkx2.1 and Lix1 expression (FIG. 7G &FIG. 8E ). These results indicate that the chemically induced astrocytes can be regionally specified. - Example 6 VCSTO-induced astrocytes are functional
- To test if compound-induced astrocytes possess astrocyte function to promote neuronal maturation and synaptic formation, the induced astrocytes were co-cultured with mouse primary cortical neurons. Neuronal maturation was evaluated by immunostaining with a mature neuronal marker, MAP2, at
day 5 after co-culture. Both total neurite length and neurite complexity were increased in neurons co-cultured with induced astrocytes or primary astrocytes, compared to that in neurons co-cultured with MEFs (FIG. 9A, 9B &FIG. 10 ). Moreover, the density of synapsin-positive puncta along the MAP2-positive neurites was significantly increased in neurons co-cultured with induced astrocytes and primary astrocytes, compared to that in neurons co-cultured with MEFs (FIG. 9C, 9D ). These results indicate that the VCSTO-induced astrocytes exhibit functional property in promoting neuronal maturation and synaptogenesis, like primary astrocytes. - Next, whether the compound-induced astrocytes were functional in glutamate uptake was determined. Primary astrocytes, induced astrocytes and parental MEFs were cultured in media containing glutamate for 6 hr, the concentration of glutamate in the media was measured to determine glutamate uptake. Both induced astrocytes and primary astrocytes exhibited substantial glutamate uptake, compared to MEFs (
FIG. 9F ), indicating that compound-induced astrocytes are functional in glutamate uptake. - Calcium imaging analysis revealed that the VCSTO-induced astrocytes exhibited glutamate-induced calcium spikes, in a manner similar to primary astrocytes, whereas MEFs did not respond to glutamate stimulation with calcium spikes (
FIG. 9G-I ). These results suggest that induced astrocytes acquire the ability to respond to neurotransmitters through calcium signaling, like primary astrocytes. In summary, the chemically induced astrocytes are functional astrocytes with the ability to promote neuronal survival and maturation, uptake glutamate and respond to calcium signaling. - Example 7 VCSTO-induced astrocytes can survive and retain astrocyte identity in vivo
- To determine if compound-induced astrocytes can survive and maintain their astrocytic identity in vivo, the VCSTO-induced astrocytes were labeled with a GFP reporter and transplanted into the lateral ventricles of immunodeficient neonatal NOD scid gamma (NSG) mice (
FIG. 11A ). Six weeks after transplantation, the grafted brains were analyzed by immunostaining. The GFP-positive grafted cells survived 6-week engraftment and continued to express GFAP in the brain (FIG. 11B, 11C ). In contrast, the control MEFs were not able to survive the engraftment in the transplanted brains (FIG. 11D ). These results indicate that the VCSTO-induced astrocytes can survive engraftment and maintain astrocytic marker expression in vivo. - Example 8 Compound-induced astrocytes can be used to model neurological disease
- AxD is a neurological disease with astrocyte dysfunction and is caused by genetic mutation of the GFAP gene (Messing et al., 2012). Expression of AxD mutant GFAP induces the expression of αβ-crystallin, a small heat shock protein, and the formation of protein aggregates containing GFAP and αβ-crystallin in astrocytes (Messing et al., 2012). The compound-induced astrocytes were tested to see if they could be used to model AxD. Plasmid expressing GFP fusion of the wild type (WT) or AxD mutant GFAP containing the R239C mutation, a hotspot mutation for AxD (Hagemann et al., 2006), were transfected into VCSTO-induced astrocytes. Expression of the AxD mutant GFAP in induced astrocytes promoted the expression of αβ-crystallin and the formation of protein aggregates immunoreactive for GFAP and αβ-crystallin, whereas transfection of the same amount of WT GFAP-GFP did not induce detectable αβ-crystallin expression and GFAP protein aggregation (
FIG. 12A ). The β-lactam antibiotic ceftriaxone has been shown to facilitate the elimination of AxD mutant GFAP protein aggregates in primary astrocytes (Bachetti et al., 2010). VCSTO-induced astrocytes transfected with the AxD mutant GFAP were treated with ceftriaxone. Substantial elimination of GFAP protein aggregates was detected in ceftriaxone-treated cells, compared to vehicle control-treated cells (FIG. 12B, 12C ). Although MEFs transduced with the AxD mutant GFAP also exhibited GFAP protein aggregates, the fibroblast aggregates were not responsive to ceftriaxone treatment (FIG. 12D ). - Moreover, glutamate uptake assay revealed that VCSTO-induced astrocytes transduced with the AxD mutant GFAP exhibited reduced glutamate uptake, compared to VCSTO-induced astrocytes transduced with WT GFAP (
FIG. 12E ). These results together suggest that compound-induced astrocytes could be used to model neurological diseases with astrocyte dysfunction and test candidate drugs for these diseases. - Example 9 VCSTO could induce astrocytic conversion from human fibrobasts
- To determine if human fibroblasts could be induced for astrocytic conversion using small molecule compounds, human foreskin fibroblasts were treated with VCSTO compounds. Forty days after compound treatment, a large number of cells with astroglial progenitor-like morphology were observed. Because S100β is a marker for human astroglial progenitor cells and astrocytes, the VCSTO-treated cells were stained for S100β and it was found that more than 30% of cells were S100β+ cells, whereas no S100β+ cells were detected in DMSO-treated cells (
FIG. 13A, 13C ). Treatment of the astroglial progenitor cells with ciliary neurotrophic factor (CNTF) for 6 days allowed the maturation of these cells into astrocytes with bigger cell body and more complex morphology. Immunostaining of the resultant cells allowed the detection of both S100β+ cells and GFAP+ cells in VCSTO-treated cells (FIG. 13B, 13C ). - In a parallel experiment, robust induction of astrocyte marker genes, GFAP, S100β, AQP4 and EAAT2, was detected in VCSTO-reprogrammed cells (iA), to a level that is similar to or higher than that in human iPSC-derived astrocytes (hA) (
FIG. 13D ). In contrast, the expression level of the astrocytic genes is much lower in DMSO-treated human fibroblasts (hF) (FIG. 13D ). Moreover, human induced astrocytes exhibited potent glutamate uptake, compared to parental fibroblasts (FIG. 13E ). Calcium imaging analysis revealed that the human iA exhibited glutamate-induced calcium signal change, similar to hA, whereas parental fibroblasts did not exhibit calcium signal change in response to glutamate stimulation (FIG. 13F ). These results together indicate that the VCSTO cocktail could induce human fibroblasts into astroglial progenitor cells that can be further matured into functional astrocytes. - To determine if adult human fibroblasts could be induced into astrocytes using small molecules, human fibroblasts derived from a 71 year-old donor were treated with the VCSTO compounds. After forty days of VCSTO compound treatment and ten days of CNTF-induced maturation, both S100β+ cells and GFAP+ cells were detected in VCSTO-treated cells, but not in DMSO-treated cells (
FIG. 13G, 13H ). RT-PCR analysis revealed potent induction of astrocyte marker genes, GFAP, S100β, SLC1A2, and EAAT2 in VCSTO-induced cells, compared to that in DMSO-treated cells (FIG. 13I ). The induced astrocytes also exhibited substantial glutamate uptake, compared to parental fibroblasts (FIG. 13J ). These results together indicate that the VCSTO compounds could induce human adult fibroblasts into functional astrocytes. - All publications and patent documents cited herein are incorporated by reference.
-
- Bachetti, T., Caroli, F., Bocca, P., Prigione, I., Balbi, P., Biancheri, R., Filocamo, M., Mariotti, C., Pareyson, D., Ravazzolo, R., et al. (2008). Mild functional effects of a novel GFAP mutant allele identified in a familial case of adult-onset Alexander disease. Eur
J Hum Genet 16, 462-470. - Bachetti, T., Di Zanni, E., Balbi, P., Bocca, P., Prigione, I., Deiana, G. A., Rezzani, A., Ceccherini, I., and Sechi, G. (2010). In vitro treatments with ceftriaxone promote elimination of mutant glial fibrillary acidic protein and transcription down-regulation. Experimental cell research 316, 2152-2165.
- Banker, G. A. (1980). Trophic interactions between astroglial cells and hippocampal neurons in culture. Science (New York, N.Y. 209, 809-810.
- Barres, B. A. (2008). The mystery and magic of glia: a perspective on their roles in health and disease.
Neuron 60, 430-440. - Bonaguidi, M. A., McGuire, T., Hu, M., Kan, L., Samanta, J., and Kessler, J. A. (2005). LIF and BMP signaling generate separate and discrete types of GFAP-expressing cells. Development (Cambridge, England) 132, 5503-5514.
- Caiazzo, M., Dell'Anno, M. T., Dvoretskova, E., Lazarevic, D., Taverna, S., Leo, D., Sotnikova, T. D., Menegon, A., Roncaglia, P., Colciago, G., et al. (2011). Direct generation of functional dopaminergic neurons from mouse and human fibroblasts. Nature 476, 224-227.
- Caiazzo, M., Giannelli, S., Valente, P., Lignani, G., Carissimo, A., Sessa, A., Colasante, G., Bartolomeo, R., Massimino, L., Ferroni, S., et al. (2015). Direct Conversion of Fibroblasts into Functional Astrocytes by Defined Transcription Factors. Stem Cell Reports.
- Calone, I., Souchelnytskyi S. (2012). Inhibition of TGF(3 signaling and Its Implications in Anticancer Treatments. Exp. Oncol. 34, 9-16.
- Cassady, J. P., D'Alessio, A. C., Sarkar, S., Dani, V. S., Fan, Z. P., Ganz, K., Roessler, R., Sur, M., Young, R. A., and Jaenisch, R. (2014). Direct lineage conversion of adult mouse liver cells and B lymphocytes to neural stem cells. Stem Cell Reports 3, 948-956.
- Chaudhry, F. A., Lehre, K. P., van Lookeren Campagne, M., Ottersen, O. P., Danbolt, N. C., and Storm-Mathisen, J. (1995). Glutamate transporters in glial plasma membranes: highly differentiated localizations revealed by quantitative ultrastructural immunocytochemistry.
Neuron 15, 711-720. - Cheng, L., Hu, W., Qiu, B., Zhao, J., Yu, Y., Guan, W., Wang, M., Yang, W., and Pei, G. (2014). Generation of neural progenitor cells by chemical cocktails and hypoxia. Cell research 24, 665-679.
- Davis, R. L., Weintraub, H., and Lassar, A. B. (1987). Expression of a single transfected cDNA converts fibroblasts to myoblasts. Cell 51, 987-1000.
- Eroglu, C., and Barres, B. A. (2010). Regulation of synaptic connectivity by glia. Nature 468, 223-231.
- Gellibert, F., Woolven, J., Fouchet, M. H., Mathews, N., Goodland, H., Lovegrove, V., Laroze, A., Nguyen, V. L., Sautet, S., Wang, R., et al. (2004). Identification of 1,5-naphthyridine derivatives as a novel series of potent and selective TGF-beta type I receptor inhibitors. Journal of medicinal chemistry 47, 4494-4506.
- Gross, R. E., Mehler, M. F., Mabie, P. C., Zang, Z., Santschi, L., and Kessler, J. A. (1996). Bone morphogenetic proteins promote astroglial lineage commitment by mammalian subventricular zone progenitor cells. Neuron 17, 595-606.
- Hagemann, T. L., Connor, J. X., and Messing, A. (2006). Alexander disease-associated glial fibrillary acidic protein mutations in mice induce Rosenthal fiber formation and a white matter stress response. J Neurosci 26, 11162-11173.
- Hama, H., Hara, C., Yamaguchi, K., and Miyawaki, A. (2004). PKC signaling mediates global enhancement of excitatory synaptogenesis in neurons triggered by local contact with astrocytes. Neuron 41, 405-415.
- Han, D. W., Tapia, N., Hermann, A., Hemmer, K., Hoing, S., Arauzo-Bravo, M. J., Zaehres, H., Wu, G., Frank, S., Moritz, S., et al. (2012). Direct reprogramming of fibroblasts into neural stem cells by defined factors.
Cell stem cell 10, 465-472. - Hatada, I., Namihira, M., Morita, S., Kimura, M., Horii, T., and Nakashima, K. (2008). Astrocyte-specific genes are generally demethylated in neural precursor cells prior to astrocytic differentiation.
PloS one 3, e3189. - Hawley, R. G. (2008). Does retroviral insertional mutagenesis play a role in the generation of induced pluripotent stem cells?
Mol Ther 16, 1354-1355. - Hou, P., Li, Y., Zhang, X., Liu, C., Guan, J., Li, H., Zhao, T., Ye, J., Yang, W., Liu, K., et al. (2013). Pluripotent stem cells induced from mouse somatic cells by small-molecule compounds. Science (New York, N.Y. 341, 651-654.
- Hu, W., Qiu, B., Guan, W., Wang, Q., Wang, M., Li, W., Gao, L., Shen, L., Huang, Y., Xie, G., et al. (2015). Direct Conversion of Normal and Alzheimer's Disease Human Fibroblasts into Neuronal Cells by Small Molecules. Cell stem cell 17, 204-212.
- Ichida, J. K., Blanchard, J., Lam, K., Son, E. Y., Chung, J. E., Egli, D., Loh, K. M., Carter, A. C., Di Giorgio, F. P., Koszka, K., et al. (2009). A small-molecule inhibitor of tgf-Beta signaling replaces sox2 in reprogramming by inducing nanog.
Cell stem cell 5, 491-503. - Inman, G. J., Nicolas, F. J., Callahan, J. F., Harling, J. D., Gaster, L. M., Reith, A. D., Laping, N. J., and Hill, C. S. (2002). SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Mol Pharmacol 62, 65-74.
- Irizarry, R. A., Hobbs, B., Collin, F., Beazer-Barclay, Y. D., Antonellis, K. J., Scherf, U., and Speed, T. P. (2003). Exploration, normalization, and summaries of high density oligonucleotide array probe level data.
Biostatistics 4, 249-264. - Kim, J., Efe, J. A., Zhu, S., Talantova, M., Yuan, X., Wang, S., Lipton, S. A., Zhang, K., and Ding, S. (2011). Direct reprogramming of mouse fibroblasts to neural progenitors. Proceedings of the National Academy of Sciences of the United States of America 108, 7838-7843.
- Kohyama, J., Sanosaka, T., Tokunaga, A., Takatsuka, E., Tsujimura, K., Okano, H., and Nakashima, K. (2010). BMP-induced REST regulates the establishment and maintenance of astrocytic identity. The Journal of cell biology 189, 159-170.
- Li, W., Tian, E., Chen, Z. X., Sun, G., Ye, P., Yang, S., Lu, D., Xie, J., Ho, T. V., Tsark, W. M., et al. (2012). Identification of Oct4-activating compounds that enhance reprogramming efficiency. Proceedings of the National Academy of Sciences of the United States of America 109, 20853-20858.
- Li, X., Zuo, X., Jing, J., Ma, Y., Wang, J., Liu, D., Zhu, J., Du, X., Xiong, L., Du, Y., et al. (2015). Small-Molecule-Driven Direct Reprogramming of Mouse Fibroblasts into Functional Neurons. Cell stem cell 17, 195-203.
- Lin, T., Ambasudhan, R., Yuan, X., Li, W., Hilcove, S., Abujarour, R., Lin, X., Hahm, H. S., Hao, E., Hayek, A., et al. (2009). A chemical platform for improved induction of human iPSCs.
Nature methods 6, 805-808. - Lujan, E., Chanda, S., Ahlenius, H., Sudhof, T. C., and Wernig, M. (2012). Direct conversion of mouse fibroblasts to self-renewing, tripotent neural precursor cells. Proceedings of the National Academy of Sciences of the United States of America 109, 2527-2532.
- Maherali, N., and Hochedlinger, K. (2009). Tgfbeta signal inhibition cooperates in the induction of iPSCs and replaces Sox2 and cMyc. Curr Biol 19, 1718-1723.
- Messing, A., Brenner, M., Feany, M. B., Nedergaard, M., and Goldman, J. E. (2012). Alexander Disease. J Neurosci 32, 5017-5023.
- Molofsky, A. V., Krencik, R., Ullian, E. M., Tsai, H. H., Deneen, B., Richardson, W. D., Barres, B. A., and Rowitch, D. H. (2012). Astrocytes and disease: a neurodevelopmental perspective. Genes & development 26, 891-907.
- Najm, F. J., Lager, A. M., Zaremba, A., Wyatt, K., Caprariello, A. V., Factor, D. C., Karl, R. T., Maeda, T., Miller, R. H., and Tesar, P. J. (2013). Transcription factor-mediated reprogramming of fibroblasts to expandable, myelinogenic oligodendrocyte progenitor cells. Nature biotechnology 31, 426-433.
- Okita, K., Nakagawa, M., Hyenjong, H., Ichisaka, T., and Yamanaka, S. (2008). Generation of mouse induced pluripotent stem cells without viral vectors. Science (New York, N.Y. 322, 949-953.
- Pang, Z. P., Yang, N., Vierbuchen, T., Ostermeier, A., Fuentes, D. R., Yang, T. Q., Citri, A., Sebastiano, V., Marro, S., Sudhof, T. C., et al. (2011). Induction of human neuronal cells by defined transcription factors. Nature 476, 220-223.
- Rajan, P., and McKay, R. D. (1998). Multiple routes to astrocytic differentiation in the CNS. J Neurosci 18, 3620-3629.
- Ring, K. L., Tong, L. M., Balestra, M. E., Javier, R., Andrews-Zwilling, Y., Li, G., Walker, D., Zhang, W. R., Kreitzer, A. C., and Huang, Y. (2012). Direct reprogramming of mouse and human fibroblasts into multipotent neural stem cells with a single factor. Cell stem cell 11, 100-109.
- Schildge, S., Bohrer, C., Beck, K., and Schachtrup, C. (2013). Isolation and culture of mouse cortical astrocytes. J Vis Exp doi: 10.3791/50079.
- Simard, M., and Nedergaard, M. (2004). The neurobiology of glia in the context of water and ion homeostasis. Neuroscience 129, 877-896.
- Smith, J. R., Vallier, L., Lupo, G., Alexander, M., Harris, W. A., and Pedersen, R. A. (2008). Inhibition of Activin/Nodal signaling promotes specification of human embryonic stem cells into neuroectoderm. Developmental biology 313, 107-117.
- Sofroniew, M. V., and Vinters, H. V. (2010). Astrocytes: biology and pathology. Acta neuropathologica 119, 7-35.
- Song, H., Stevens, C. F., and Gage, F. H. (2002). Astroglia induce neurogenesis from adult neural stem cells. Nature 417, 39-44.
- Szabo, P. E., Hubner, K., Scholer, H., and Mann, J. R. (2002). Allele-specific expression of imprinted genes in mouse migratory primordial germ cells. Mechanisms of development 115, 157-160.
- Takahashi, K., and Yamanaka, S. (2006). Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126, 663-676.
- Thier, M., Worsdorfer, P., Lakes, Y. B., Gorris, R., Herms, S., Opitz, T., Seiferling, D., Quandel, T., Hoffmann, P., Nothen, M. M., et al. (2012). Direct conversion of fibroblasts into stably expandable neural stem cells.
Cell stem cell 10, 473-479. - Tojo, M., Hamashima, Y., Hanyu, A., Kajimoto, T., Saitoh, M., Miyazono, K., Node, M., and Imamura, T. (2005). The ALK-5 inhibitor A-83-01 inhibits Smad signaling and epithelial-to-mesenchymal transition by transforming growth factor-beta. Cancer Sci 96, 791-800.
- Verkhratsky, A., Sofroniew, M. V., Messing, A., Delanerolle, N. C., Rempe, D., Rodriguez Arellano, J. J., and Nedergaard, M. (2012). Neurological diseases as primary gliopathies: A reassessment of neurocentrism. ASN neuro doi: 10.1042/AN20120010.
- Vierbuchen, T., Ostermeier, A., Pang, Z. P., Kokubu, Y., Sudhof, T. C., and Wernig, M. (2010). Direct conversion of fibroblasts to functional neurons by defined factors. Nature 463, 1035-1041.
- Wang, D. D., and Bordey, A. (2008). The astrocyte odyssey. Progress in neurobiology 86, 342-367.
- Xu, R. H., Sampsell-Barron, T. L., Gu, F., Root, S., Peck, R. M., Pan, G., Yu, J., Antosiewicz-Bourget, J., Tian, S., Stewart, R., et al. (2008). NANOG is a direct target of TGFbeta/activin-mediated SMAD signaling in human ESCs.
Cell stem cell 3, 196-206. - Yang, N., Zuchero, J. B., Ahlenius, H., Marro, S., Ng, Y. H., Vierbuchen, T., Hawkins, J. S., Geissler, R., Barres, B. A., and Wernig, M. (2013). Generation of oligodendroglial cells by direct lineage conversion. Nature biotechnology 31, 434-439.
- Yoo, A. S., Sun, A. X., Li, L., Shcheglovitov, A., Portmann, T., Li, Y., Lee-Messer, C., Dolmetsch, R. E., Tsien, R. W., and Crabtree, G. R. (2011). MicroRNA-mediated conversion of human fibroblasts to neurons. Nature 476, 228-231.
- Zhang, L., Yin, J. C., Yeh, H., Ma, N. X., Lee, G., Chen, X. A., Wang, Y., Lin, L., Chen, L., Jin, P., et al. (2015). Small Molecules Efficiently Reprogram Human Astroglial Cells into Functional Neurons. Cell stem cell 17, 735-747.
- Zhuo, L., Sun, B., Zhang, C. L., Fine, A., Chiu, S. Y., and Messing, A. (1997). Live astrocytes visualized by green fluorescent protein in transgenic mice. Developmental biology 187, 36-42.
Claims (15)
1. A method of preventing or treating a neurodegenerative disease associated with astrocyte dysfunction in a subject, comprising:
reprogramming or converting somatic tissue or cells into astrocytes or astroglial progenitor cells by contacting the somatic tissue or cells with one or more small molecules, wherein the one or more small molecules include at least one TGF-β inhibitor; and
transplanting the astrocytes or astroglial progenitor cells into the brain of the subject.
2. The method of claim 1 , further comprising isolating the somatic tissue or cells from the subject before reprogramming.
3. The method of claim 1 , wherein the subject is human.
4. The method of claim 1 , wherein the somatic tissue or cells are fibroblasts, urinary cells, blood cells, adipocytes, keratinocytes, or dental pulp cells.
5. The method of claim 1 , wherein a single small molecule is used and the small molecule is a TGF-β inhibitor.
6. The method of claim 5 , wherein the TGF-β inhibitor is an inhibitor of TGF-βR1 (ALK5).
7. The method of claim 5 , wherein the TGF-β inhibitor is 616452, SB-431542, A-83-01, SD-208, LY 2109761, GW 788388, LDN-212854, A 77-01, LY2157299, K02288, ML347, or SB-505124 hydrochloride.
8. The method of claim 1 , wherein the one or more small molecules further include at least one of a histone deacetylase inhibitor, a GSK3β inhibitor, a lysine specific histone demethylase 1 (LSD1) inhibitor, and an Oct4-activating compound.
9. The method of claim 8 , wherein the one or more small molecules are a combination of VPA (V), CHIR99021 (C), 616452 (6), tranylcypromine (T), and OAC1 (O), a combination of VPA (V), CHIR99021 (C), A-83-01 (A), tranylcypromine (T), and OAC1 (O), or a combination of VPA (V), CHIR99021 (C), SB-431542 (S), tranylcypromine (T), and OAC1 (O).
10. A combination of small molecules comprising a TGF-β inhibitor, wherein the combination induces or promotes reprogramming or converting somatic tissue or cells into astrocytes or astroglial progenitor cells.
11. The combination of claim 10 , further comprising at least one of a histone deacetylase inhibitor, a GSK3β inhibitor, a lysine specific histone demethylase 1 (LSD1) inhibitor, and an Oct4-activating compound.
12. The combination of claim 10 , wherein the combination is a combination of VPA (V), CHIR99021 (C), 616452 (6), tranylcypromine (T), and OAC1 (O), a combination of VPA (V), CHIR99021 (C), A-83-01 (A), tranylcypromine (T), and OAC1 (O), or a combination of VPA (V), CHIR99021 (C), SB-431542 (S), tranylcypromine (T), and OAC1 (O).
13. A composition comprising a combination of small molecules, wherein the combination induces or promotes reprogramming or converting somatic tissue or cells into astrocytes or astroglial progenitor cells, and wherein the combination comprises a TGF-β inhibitor.
14. The composition of claim 13 , wherein the combination further comprises at least one of a histone deacetylase inhibitor, a GSK3β inhibitor, a lysine specific histone demethylase 1 (LSD1) inhibitor, and an Oct4-activating compound.
15. The composition of claim 13 , wherein the combination is a combination of VPA (V), CHIR99021 (C), 616452 (6), tranylcypromine (T), and OAC1 (O), a combination of VPA (V), CHIR99021 (C), A-83-01 (A), tranylcypromine (T), and OAC1 (O), or a combination of VPA (V), CHIR99021 (C), SB-431542 (S), tranylcypromine (T), and OAC1 (O).
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/656,999 US20220273655A1 (en) | 2016-06-22 | 2022-03-29 | Producing astrocytes using small molecules |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662353214P | 2016-06-22 | 2016-06-22 | |
PCT/US2017/038611 WO2017223241A1 (en) | 2016-06-22 | 2017-06-21 | Producing astrocytes using small molecules |
US201816311965A | 2018-12-20 | 2018-12-20 | |
US17/656,999 US20220273655A1 (en) | 2016-06-22 | 2022-03-29 | Producing astrocytes using small molecules |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/311,965 Division US11413286B2 (en) | 2016-06-22 | 2017-06-21 | Producing astrocytes using small molecules |
PCT/US2017/038611 Division WO2017223241A1 (en) | 2016-06-22 | 2017-06-21 | Producing astrocytes using small molecules |
Publications (1)
Publication Number | Publication Date |
---|---|
US20220273655A1 true US20220273655A1 (en) | 2022-09-01 |
Family
ID=60784892
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/311,965 Active 2038-09-15 US11413286B2 (en) | 2016-06-22 | 2017-06-21 | Producing astrocytes using small molecules |
US17/656,999 Abandoned US20220273655A1 (en) | 2016-06-22 | 2022-03-29 | Producing astrocytes using small molecules |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/311,965 Active 2038-09-15 US11413286B2 (en) | 2016-06-22 | 2017-06-21 | Producing astrocytes using small molecules |
Country Status (2)
Country | Link |
---|---|
US (2) | US11413286B2 (en) |
WO (1) | WO2017223241A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20210246421A1 (en) * | 2018-07-10 | 2021-08-12 | Kataoka Corporation | Production method for neuron-like cells |
US20230235036A1 (en) * | 2020-06-05 | 2023-07-27 | The J. David Gladstone Institutes, a testamentary trust established under the Will of J. David Glads | Acvr1 (alk2) receptor inhibition to treat neurological diseases |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8298825B1 (en) | 2008-08-25 | 2012-10-30 | The General Hospital Corporation | TGF-beta receptor inhibitors to enhance direct reprogramming |
WO2011091048A1 (en) | 2010-01-19 | 2011-07-28 | The Board Of Trustees Of The Leland Stanford Junior University | Direct conversion of cells to cells of other lineages |
WO2012014207A2 (en) * | 2010-07-27 | 2012-02-02 | Technion Research & Development Foundation Ltd. | Method for generating induced pluripotent stem cells from keratinocytes derived from plucked hair follicles |
JP6143027B2 (en) * | 2012-12-28 | 2017-06-07 | 国立大学法人京都大学 | How to induce astrocytes |
US20150250824A1 (en) * | 2014-03-07 | 2015-09-10 | The Research Foundation For The State University Of New York | Methods and compositions for expansion of stem cells and other cells |
WO2017027280A1 (en) * | 2015-08-07 | 2017-02-16 | The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone | Chemical reprogramming to generate neuronal cells |
-
2017
- 2017-06-21 US US16/311,965 patent/US11413286B2/en active Active
- 2017-06-21 WO PCT/US2017/038611 patent/WO2017223241A1/en active Application Filing
-
2022
- 2022-03-29 US US17/656,999 patent/US20220273655A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US11413286B2 (en) | 2022-08-16 |
WO2017223241A1 (en) | 2017-12-28 |
US20190175597A1 (en) | 2019-06-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6756786B2 (en) | Midbrain dopamine (DA) neurons for transplantation | |
Tian et al. | Small-molecule-based lineage reprogramming creates functional astrocytes | |
Lamba et al. | Neural regeneration and cell replacement: a view from the eye | |
JP6262205B2 (en) | Induction of neural stem cells and dopaminergic neurons from human pluripotent stem cells | |
WO2017005136A1 (en) | Compositions and methods for reprograming non-neuronal cells into neuron-like cells | |
JP6316938B2 (en) | Method for preparing induced neural stem cells reprogrammed from non-neuronal cells using HMGA2 | |
US20220273655A1 (en) | Producing astrocytes using small molecules | |
Su et al. | Direct conversion of fibroblasts into neural progenitor-like cells by forced growth into 3D spheres on low attachment surfaces | |
Deleidi et al. | Oct4-induced reprogramming is required for adult brain neural stem cell differentiation into midbrain dopaminergic neurons | |
US10087417B2 (en) | Three-dimensional model of human cortex | |
US11773369B2 (en) | Generation of human spinal cord neural stem cells | |
US20230233617A1 (en) | Methods for differentiating stem cells into dopaminergic progenitor cells | |
Prakash et al. | Efficient generation of tyrosine hydroxylase-expressing dopamine-producing neurons from rat peripheral blood progenitors using a combination of growth factors and biomimetic matrix. Arch Clin Biomed Res | |
White | Enrichment for V1 interneurons from mouse embryonic stem cells and evaluation of de novo network formation | |
Terrigno | Study of cortical and hippocampal specification using embryonic stem cell-derived neurons | |
Ali | Stem Cell In-vitro Strategies for the Induction of Sensory Neurons for Inner Ear Cell Therapy | |
EA041083B1 (en) | METHOD FOR INDUCING DIFFERENTIATION OF PLURIPOTENT STEM CELLS IN VITRO |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: CITY OF HOPE, CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SHI, YANHONG;TIAN, E.;SIGNING DATES FROM 20190326 TO 20190328;REEL/FRAME:059551/0024 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |